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ABSTRACT 
Chemotherapy and radiation therapy are the most widely used interventions for the treatment 
of cancer. Several adverse effects including mucositis are associated with these therapies, 
which affect a patient’s quality of life, resulting in morbidity and mortality. Cancer therapy 
also causes an imbalance in the oral flora which allows colonization of the oral cavity with 
uncommon bacteria, including aerobic gram negative bacteria and less commonly, Candida. 
These organisms can become established in the lesions of oral mucositis. These gram 
negative bacteria produce endotoxins. Although the involvement of endotoxins in the 
development of systemic infections is well described, the role of endotoxins in oral mucositis 
is not known. Therefore, this study investigated the presence of aerobic gram negative 
bacteria and endotoxins in the oral cavities of patients receiving cancer treatment and their 
role in the development of oral mucositis. 
 
Oral cavity rinse samples were collected from 100 cancer patients on cancer treatment and 50 
healthy individuals. Ethical clearance was obtained from The Committee for Research on 
Human Subjects (Medical). The demographic and clinical data were recorded. Samples were 
serially diluted and cultured onto Mitis Salivarius Agar for Streptococci, Baird Parker Agar 
for Staphylococcus aureus, MacConkey Agar for aerobic gram negative bacteria (AGNB) 
and Chromagar for Candida species. Colony counts were obtained and the cultures of AGNB 
and Candida species were further identified at the species level using the API technique. An 
antimicrobial susceptibility test was performed on AGNB. Oral rinse samples were further 
tested for the presence of endotoxin using the Hycult Biotech Limulus Amebocyte Lysate 
(LAL) assay. Results were analysed using the Mann-Whitney and chi-square test. P-values of 
≤ 0.05% were considered significant.  
Eighty percent of cancer patients were females with breast (58%) or cervical cancer (9%). 
The majority of these patients were on chemotherapy (61%), were receiving a combination of 
chemotherapeutic drugs and had completed many cycles of chemotherapy treatment. Twelve 
percent of patients had oral mucositis of various grades. Healthy individuals also comprised 
of mainly females (76%). All cancer patients and 98% of healthy individuals carried 
Streptococci. No significant difference in the carriage of S. aureus was found between the 
two groups. However, the Candida carrier rate was significantly high in cancer patients 
(55%) compared to the healthy (20%) individuals (p<0.01). Although the Candida counts 
were not different between the groups (p>0.05), cancer patients carried a variety of Candida 
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species and some patients carried more than one type of Candida species in their oral cavity. 
In addition, C. glabrata was only found in cancer patients. Between the groups of cancer 
patients and healthy individuals, no significant difference in the carrier rate of AGNB was 
found (cancer 24% vs 14% healthy). However, cancer patients carried a variety of AGNB. 
Enterobacter cloacae and Klebsiella pneumonia was isolated from the oral cavities of both 
the study groups. These bacteria were resistant to many antibiotics. When the prevalence of 
these oral bacteria was compared between patients with and without oral mucositis, it was 
found that the percentage prevalence of Candida species was significantly high in patients 
with oral mucositis.  
A mean endotoxin concentration of 3.65ng/ml and 3.37ng/ml was detected in the oral rinse 
samples of cancer patients and healthy individuals respectively. The difference in the 
endotoxin between the two groups was not significant (p=0.5). Mean values of 4.1ng/ml and 
3.53ng/ml were found in cancer patients with and without oral mucositis respectively. The 
difference in the quantities of endotoxins between the two groups was not significant (p=0.6). 
In addition, endotoxin present in cancer patients with AGNB (3.39ng/ml) and without AGNB 
(3.8ng/ml) was also not significantly different. 
These results suggest that although cancer patients carry aerobic gram negative bacteria and 
endotoxins in their oral cavities, they may not contribute in the exacerbation of oral 
mucositis. However, Candida species may contribute in the exacerbation of oral mucositis 
and therefore, during cancer treatment, it is important to take preventative measures to reduce 
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CHAPTER 1 




The development of cancer arises from the mutagenesis of normal cells from a particular 
organ as a result of the interaction of complex aetiologies. Various treatment modalities are 
used but intensive chemotherapy and radiotherapy are conventionally required. Several 
adverse effects including mucositis are associated with these therapies, which affect a 
patient’s quality of life, resulting in morbidity and mortality. Oral mucositis is associated 
with immense oral discomfort, excruciating pain, an altered taste sensation, painful 
swallowing and subsequent dehydration and malnutrition. Due to the loss of balance between 
commensal bacteria and opportunistic bacteria, changes in the oral environment and 
microbiome occurs. Some of these opportunistic bacteria such as gram negative bacteria and 
Candida species become established in the lesions of oral mucositis. These gram negative 
bacteria produce endotoxins and Candida species produce hydrolytic enzymes as virulence 
factors. The endeavour to find an efficient solution to manage and prevent this pathology has 
been challenging. The efficacy of antimicrobials and other treatment modalities have been 
controversial. Although the involvement of endotoxins in the development of other bacterial 
infections is well described, the role of endotoxins in oral mucositis is not known. Therefore, 
this study investigated the presence of aerobic gram negative bacteria and endotoxins in the 













   
1 Literature Review 
1.1 Cancer epidemiology 
 
Cancer-related deaths have reached epic proportions, both in South Africa and 
internationally. This pandemic has amounted to approximately 8.2 million cancer-related 
deaths in 2012 and an incidence of 14.1 million cancer cases reported every year 
(GLOBOCAN 2012). By 2030, this is expected to rise to 21.7 million new cancer cases and 
13 million cancer deaths (GLOBOCAN 2012). In recent articles (Stefan et al, 2013 and 
Sartorius et al, 2016), by 2030, South African cancer rates have been predicted to escalate by 
78%. Cancer can arise from a complex aetiology affecting various cells and organs (Baskar et 
al, 2012). Although the incidence and mortality rates in western developed countries have 
decreased, almost half the number of reported incidences worldwide has been related to lung, 
female breast, colorectal and stomach malignancies (Jemal et al, 2010). Lifestyle factors such 
as smoking, alcohol, a sedentary lifestyle and obesity are risk factors seen in western 
countries, but increased incidences in cervical, liver and stomach cancers, have been related 
to cancers developing from infectious agents in underdeveloped countries and improved 
socioeconomic countries (Jemal et al, 2010).  
 
The habitual use of tobacco and alcohol are predominant risk factors in the development of 
head and neck carcinomas. In less developed countries, carcinogenic infection is an important 
cause of cancer. Of concern, oncogenic viruses such as the Epstein- Barr virus, Human 
papillomavirus virus (HPV) and Helicobacter pylori have been linked to endemic 
nasopharyngeal cancer, oropharyngeal cancers and gastric cancer respectively (Jemal et al, 
2010; Schoenfeld, 2015 and Plummer et al, 2016 ).  The development of HIV-related cancers 
has been associated with immunosuppression and the increased expression of carcinogenic 
infectious agents (IARC, 2012 and Plummer et al, 2016).  Many cases of fatalities could be 
prevented in countries where HIV and HPV are prevalent, by implementing screening 
procedures, proper diagnosing and treatment of precancerous lesions (Crosbie et al, 2013 and 




   
Various other risk factors are commonly associated with cancer, including prolonged sun 
exposure, demographic factors, occupational inhalants, marijuana use, poor nutrition and 
immunosuppression (Khan and Khan, 2015).  Family history and pre-existing medical 
conditions play a significant role (Pai and Westra, 2009; and Khan and Khan, 2015). 
Hormone replacement therapy and oral contraceptives may increase the risk of some cancers 
but decrease it for others. Ironically, specific chemotherapy agents such as Chlorambucil 
have been found to allow growth of cancer at a different anatomical site (American Cancer 
Society, 2014). 
 
1.2 Cancer treatment 
Most cancers are treated with surgery, radiotherapy, chemotherapy and immunotherapy 
(Payne and Miles, 2008). The choice of treatment depends on the site, grade and stage of 
tumor, as well as the patient’s age and general medical condition (Khan and Khan, 2015). 
Surgery with complete tumour resection, radiotherapy and /or chemotherapy are used to treat 
most early stages of cancer, but stage III and IV malignancies may require adjuvant 
radiotherapy and chemotherapy for effective tumour regression and organ preservation for 
better survival (Caballero et al, 2009 and Alvarez et al, 2015). Surgery can be aggressive, 
consequently affecting aesthetics and function and therefore can affect the patient both 
socially and psychologically. Regardless of treatment, recurrence of the tumour can occur at 
the same region and if distant metastasis occurs, death can be inevitable (Alvarez et al, 2015). 
 
Radiotherapy requires high doses of ionizing radiation to directly damage the cellular DNA 
or indirectly damage DNA by free radicles. This deprives cancer cells and interferes with its 
multiplication potential to cause eventual death of cancer cells (Baskar et al, 2012). The 
rationale of using radiotherapy prior to surgery is to shrink the size of the tumour, but post-
surgical radiation will target undetectable tumour cells that may have persisted (Baskar et al, 
2012). This can be applied internally either in close proximity of the tumour or into the tumor 
(brachytherapy) or more commonly externally (teletherapy) (Baskar et al, 2012 and Alvarez 
et al, 2015). Administration of external radiotherapy varies from a short duration or up to 
several weeks. A cumulative dose between 50-70 Gy for solid epithelial tumours is received, 
which is sub-divided over a period of approximately two months, of which a daily dose of 
2Gy is received from Monday to Friday with a rest period of two days (Jham and Freire, 
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2006). Moreover, this allows the tumour to receive the maximum required dosage of 
radiation, thereby excluding the adjacent healthy tissues from toxicity of the treatment. The 
period of rest during the weekend allows for re-oxygenation of tumour cells, increases its 
sensitivity towards the treatment and allows for healthy cells to repopulate tissues (Joiner and 
van der Kogel, 2009; and Alvarez et al, 2015). 
 
The principle of chemotherapy is to interfere with replicating cancer cells within the various 
phases of the cell cycle, thereby causing selective cell death and inhibiting tumour growth 
(Sak, 2012 and Alvarez et al, 2015). This cocktail of drugs, work in synergy to reduce the 
development of resistance and to allow for better efficacy of treatment, without injuring the 
host (Sak, 2012 and Alvarez et al, 2015). Cytotoxic drugs such as methotrexate and 
vincristine are active at specific periods in the cell cycle to kill proliferating cells and are 
affected by the duration of exposure. Chemotherapeutic agents such as chlorambucil and 
cisplatin can efficiently target tumour cells throughout the whole cell cycle and their degree 
of cytotoxicity is dose dependant (Payne and Miles, 2008 and Sak, 2012). Adjuvant 
chemotherapy is required if there is a known risk of relapse, due to the aggressive nature of 
the cancer. As there is a lack of specificity towards cancer cells and normal rapidly dividing 
cells, with certain cytotoxic drugs such as 5- fluorouracil and cisplatin, these result in   
adverse effects of bone marrow suppression, loss of hair, mucositis, nausea and vomiting, 
which have been associated with the morbidity of this treatment (Payne and Miles, 2008). 
 
1.2.1 Oral effects of radiotherapy 
Intraorally, acute complications can arise as a result of salivary hypofunction from direct 
injury of the salivary glands by radiation. This can be reversible, although irreversible and 
permanent xerostomia can affect the volume and quality of saliva produced. Xerostomia can 
temporarily affect the sense of taste which affects a patient’s appetite and nutritional status, 
but permanent side effects of a reduction or loss in taste can persist (Alvarez et al, 2015). 
 
The sparse volume of saliva becomes more viscous and the buffering capacity is reduced, 
with a change in the salivary electrolyte concentration and the compromise of the host’s oral 
defence system (Kielbassa et al, 2006, Naidu et al, 2004 and Gupta et al, 2015). Oral 
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tenderness, tooth decay, oral disease and difficulty in swallowing are common complaints 
associated with this treatment. It accounts for a reduction in oral clearance, allowing for an 
acidic environment to persist and the emergence of cariogenic bacteria such as Streptococcus 
mutans and Lactobacillus, as seen in a study by Epstein et al, (1998).  
These cancer patients are more likely to develop periodontitis, bacterial and viral infections 
and oral candidosis (from Candida species) associated with immunosuppression (Gupta et al, 
2015 and Jham and Freire et al, 2006).  The emergence of opportunistic infections, largely 
due to Candida infections, is associated with radiation-related hyposalivation, the presence of 
oral prostheses, poor oral care and vices such as tobacco smoking and the consumption of 
alcoholic beverages. Although topical antifungal drugs are the treatment of choice for this 
infection, systemic medication is frequently recommended for patients undergoing 
radiotherapy (Meurman and Grönroos, 2010 and Alvarez et al, 2015). One of the most 
common complications associated with patients undergoing head and neck radiotherapy is 
oral mucositis. Late complications of radiotherapy can result in trismus and 
osteoradionecrosis (Alvarez et al, 2015). 
 
1.2.2 Oral complications of chemotherapy 
The direct effects of stomatotoxicity, depends on the type of chemotherapeutic agent used, 
the dosage and frequency. Agents such as cisplatin, 5- fluorouracil and methotrexate are used 
in the treatment head and neck cancers, are known to cause mucosal injury as seen in a study 
by Kasettya et al, (2012) and consequently, conditions such as oral mucositis and microbial 
infections develop (Kasettya et al, 2012). The outcome of this mucosal atrophy is attributed 
to the cytotoxic effects of these drugs on the genetic replication and proliferation of basal 
cells of the mucosa (Lopez et al, 2011 and Kasettya et al, 2012). Lopez et al, (2012) 
concluded that indirect stomatotoxicity was related to signs of bone marrow suppression, 
immunosuppression and a loss of the host’s salivary defence mechanisms against infection 





   
1.2.3 Oral complications of chemoradiation 
The combination of radiotherapy and chemotherapy improves therapeutic results, allows for 
better tumor control in the region and controls distant metastasis (Joiner and van der Kogel, 
2009; and Alvarez et al, 2015). Consequently, high daily doses and total cumulative doses of 
radiotherapy to an exposed area, in combination with cytotoxic treatment, can affect the 
incidence, severity and duration of the complication (Jham and Freire et al, 2006). The 
complications of chemoradiation are similar to the oral complications associated solely from 
either treatment, but are significantly accentuated (Kasettya et al, 2012). 
1.3 Oral Mucositis 
The complications associated with cytotoxic treatment can have a significant impact on 
various mucosal tissues in the gastrointestinal tract, including the oral cavity, oesophagus, 
stomach and intestine. Symptoms of pain, ulceration, nausea and vomiting, diarrhoea and 
rectal bleeding have been reported, depending on the area affected. Individuals experience 
different degrees of mucosal injury across different sites within the gastrointestinal tract (Al-
Dasooqi et al, 2013). 
 
Oral mucositis is a debilitating, acute, multifactorial complication associated with cancer 
patients receiving radiotherapy, chemotherapy or hematopoietic stem cell transplantation 
(HSCT) (Vozza et al, 2015). Clinical symptoms of severe oral pain, bleeding and ulceration 
can affect the person’s quality of life and delay the management of cancer. Hospitalization 
and additional use of antibiotics and parenteral opioid analgesics delays cancer treatment 
(Naidu et al, 2004 and Vozza et al, 2015). As the severity of oral mucositis and pain 
heightens, their oral intake is restricted and patients may require the insertion of a feeding 
tube for their nutritional requirements and the intake of multiple drugs. Severe oral mucositis 
is commonly found in patients that receive radiation of the oral cavity and surrounding 
structures and those treated with HSCT, as these patients have prolonged and intense 
myelosuppression. It is less frequently seen as a complication of chemotherapy in treating 
solid tumours, but it is most severe when the patient has underlying neutropenia (Redding, 
2005). 
 
With the initiation of treatment, when doses reach up to 20Gy at the field of radiation or 
within two weeks of initiating chemotherapy, either transient hyperkeratinisation or erythema 
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develops. Multiple, daily, fractioned radiotherapy may result in repeated tissue damage 
(Redding, 2005 and Vozza et al, 2015) and eventually lead to ulceration covered by a 
pseudomembrane and healing can take up to six weeks following the completion of treatment 
(Vozza et al, 2015). The severity of radiotherapy-related oral mucositis is affected by factors 
surrounding the treatment such as the cumulative dose, the volume of area undergoing 
radiation and predisposing patient factors such as habitual use of cigarette smoking, alcohol 
consumption (Köstler et al, 2001 and Naidu et al, 2004) and radiation-induced xerostomia as 
seen in a study by Franzén et al, (1992). 
 
Oral mucositis associated with chemotherapy is restricted to non-keratinized oral mucosal 
tissue with healing and resolution occurring three weeks after the end of treatment (Redding, 
2005). This severity is also related to the neutropenic state of the patient. The combined 
effects of the type of chemotherapeutic agent used, the therapeutic regimen, the dosage and 
the concomitant medication, can affect the severity of ulceration. Lower doses of cytotoxic 
agents with prolonged or repetitive administration and prior episodes of chemotherapy-
induced oral mucositis have been implicated in affecting the severity (Köstler et al, 2001).   
 
1.3.1 Aetiology of oral mucositis 
Some of these risk factors associated with oral mucositis include age, particularly younger 
patients, poor oral health care and hyposalivation before and during treatment. Compromised 
nutrition, the type of malignancy, the neutrophil count before treatment and the underlying 
genetic predisposition are factors contributing to this pathology (Naidu et al, 2004). There is a 
higher chance of stomatotoxicity with the use of 5-fluorouracil (5-FU) in combination with 
anthracycline-based, taxane-based or platinum-based chemotherapeutic drugs (Redding, 
2005). Methotrexate found in saliva contributes to the development of oral mucositis. When 
used in combination with drugs such as antidepressants, which have an anticholinergic effect, 
can promote xerostomia and enhance the symptoms of oral mucositis (Naidu et al, 2004). 
Chemoradiation is a choice of treatment to allow for better cancer response, but 
consequently, it is proportionally responsible for the high oral mucositis rates (Redding, 
2005). Any form of iatrogenic trauma such as ill-fitting dentures and defective restorations 
can initiate ulceration. Cancer patients are prone to oral mucosal infections of bacterial, viral 
and fungal aetiology, and these can exacerbate oral mucositis with the resultant ulceration 
acting as a portal of entry for these organisms into the systemic circulation (Redding, 2005). 
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Other factors include the substitution of gram-positive bacteria for gram-negative bacteria as 
a result of the tumour, the cancer treatment and supportive therapies (Donelly et al, 2003 and 
De Sanctisa et al, 2016). Alcohol consumption predisposes the patient to malnutrition and 
immunosuppression; and the accumulation of alcoholic toxic metabolites allows for mucosal 
damage, thereby enhancing the progression of oral mucositis. Cigarette smoking elicits 
mucosal inflammation and causes the host defence mechanism to be vulnerable to infectious 
agents and therefore compromising the healing of oral mucositis (De Sanctisa et al, 2016). 
 
1.3.2 Pathophysiology of oral mucositis 
The pathology of oral mucositis can be divided into various phases. The first phase involves 
the initiation of oral mucositis. Direct injury to the basal cellular epithelium occurs due to 
DNA strand breaks and the generation of oxidative stress and reactive oxygen species (ROS) 
by radiation and/or chemotherapeutic agents.  This ROS directly damages the mucosal cells, 
tissues and blood vessels and it also stimulates the release of transcription factors which 
initiates this toxicity in the mouth (Sonis et al, 2004). 
 
During the second phase, injury to the DNA strands and the ROS, activate transcription 
factors such as Nuclear factor-κB (NF-κB). Proinflammatory cytokines such as tumour 
necrosis factor- α (TNF-α), Interleukin-1β (IL-1β), and Interleukin-6 (IL-6) are produced 
contributing towards tissue injury and apoptosis. Apoptosis can also be activated by the 
ceramide pathway with the production of sphingomyelinase or ceramide synthase. With the 
destruction of fibronectin, the activated macrophages activate matrix metalloproteinases 
(MMPs) that cause direct tissue injury (Sonis et al, 2004 and Redding, 2005).  NF-κB also 
upregulates genes to activate cyclooxygenase-2 (COX-2), which causes inflammation, 
oedema and tissue damage with the production of prostaglandin from the submucosal 
fibroblasts and endothelial cells after two weeks of radiation (Al-Dasooqi et al, 2013). 
 
In the signalling and amplification stage, proinflammatory cytokines indirectly exaggerate 
mucosal injury. A further production of cytokines allow further tissue injury via other 
pathways like the ceramide and caspase pathway and NF-κB activates the transcription 
pathway (Sonis et al, 2004).  
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The ulcerative phase is the most clinically significant phase associated with pain, oral 
discomfort and loss of function, as the mucosa is breached and the neuronal endings are 
exposed (Redding, 2005). Pathogenic bacterial colonization of gram positive, gram negative 
and anaerobic bacteria, occur. The presence of endotoxins released from the cell walls of 
gram negative bacteria, further stimulate the production of proinflammatory cytokines such 
as TNF-α , IL-1β ,  IL-6, which amplify and accelerate local tissue damage to form ulcers and 
allows the  ingress of endotoxins through the mucosal tissues and into the systemic 
circulation and possibly causing sepsis (Sonis  et al, 2004). Secondary infection is common in 
this phase and patients with neutropenia are more likely to develop complications such as 
bacteraemia, viral, fungal infections and sepsis (Al-Dasooqi et al, 2013). 
 
In the healing phase, there is renewed cell production and angiogenesis. The commensal 
bacteria are re-established and the leukopenia is resolved. Although the mucosa eventually 
has a healthy appearance, the epithelium remains significantly altered increasing the risk for 
future episodes of oral mucositis (Redding, 2005). 
 
1.3.3 Clinical presentation of oral mucositis 
Oral mucositis may begin within two weeks of commencing chemotherapy and it resolves 
within three weeks of completing the cancer treatment. This may depend on the dose, 
duration, course of treatment and the patient’s personal experience. The initial presentation 
begins with generalized burning or sensitivity of the delicate oral mucosa or in some cases 
with leukoedema (Köstler et al, 2001 and Redding, 2005). Areas of erythema and atrophy of 
the mucosa lead to the emergence of ulcers that may be covered by a pseudomembrane. 
These ulcers present with a tendency to bleed as many of these patients have 
thrombocytopaenia (Naidu et al, 2004). 
 
With the emergence of ulcers in the oral cavity and oropharyngeal region, mild or intense 
pain may be experienced, which result in poor nutrition and hydration and this affects their 
oral care. Decreased salivary flow as a complication of cancer treatment allows poor 
lubrication with the accumulation of debris in the mouth and signs of a hairy tongue may be 
observed.  
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The World Health Organization Oral Toxicity Scale (WHO, 1979) is routinely used to 
evaluate oral mucositis clinically. Grade 0 has no signs or symptoms of oral mucositis. Grade 
I oral mucositis presents with painless ulcers, erythema and oedema but patients are able to 
eat. Grade II is categorized by its painful erythema and ulcers and the presence of oedema but 
they are able to eat. With progression, the ulcers become more painful, erythematous and 
oedematous and the patient is unable to eat in Grade III. If the previous symptoms persist, but 
without the ability to eat or drink, Grade IV oral mucositis is present, where patients may 
require parenteral or enteral support (Sonis et al, 2004 and Naidu et al, 2004). 
 
Adapted from [http://www.prothelial.com/oral_mucositis/index.html] 
Figure 1.1 Various grades of oral mucositis 
 
 1.3.4 Management of oral mucositis 
The first approach taken in the management of oral mucositis has been to practice better oral 
care, to ultimately reduce the frequency and extremity of this pathology. Studies have shown 
that enforcing strict oral care protocols and managing pre-existing periodontal and dental 
disease, showed better control of this oral injury (Eilers and Million, 2011 and Lalla et al, 
2008). By delivering a known volume of radiation to a precisely demarcated irregular-shaped 
diseased region, alleviates high doses of radiation to surrounding healthy tissue, as used when 
defining the Planned Target Volume of the radiation beam (Kouloulias et al, 2013 and De 
Sanctisa et al, 2016).  
 
Treatment modalities such as cryotherapy, the use of Amifostine and glutamine, have been 
suggested, but these have proven ineffective (De Sanctisa et al, 2016). Controversy also 
exists with the use of topical antibacterial mouthwashes such as 0.12% chlorhexidine 
digluconate to reduce oral mucositis and candidosis (Lopez et al, 2011 and De Sanctisa et al, 
2016). 
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Several combinations of topical antimicrobials have been incorporated to develop a solution 
to prevent and treat oral mucositis, but results have been controversial. By integrating 
polymyxin, tobramycin, and amphotericin B (PTA) in the form of an antimicrobial lozenge, 
this eliminated selective oral flora, but it did not accomplish the role of reducing the severity 
of oral mucositis (Saunders et al, 2013 and Stokman et al, 2003). Similarly, many other 
antibiotics and treatment modalities have been suggested (Donnelly et al., 2003; Laheij et al, 
2012 and Spijkervet et al, 1990). Studies have shown that systemic antibiotics, antivirals or 
antifungals are recommended for preventative use, but only in the presence of neutropenia 
(Saunders et al, 2013). Therapeutic treatment may be required if a prominent infection has 
been diagnosed and the causative agent is identified (Saunders et al, 2013 and Bergmann et 
al, 1995). As most antibiotic interventions have not been consistently successful, this may 
suggest that the microbial flora might not be the primary culprit in initiating oral mucositis 
(Napeñas et al, 2010 and Al-Dasooqi et al, 2013). 
 
1.4 Microbiology of the oral cavity during cancer treatment 
Chemoradiation may induce an alteration of the oral environment resulting in a loss of 
balance between oral commensal bacterial flora and the emergence of opportunistic bacteria. 
The systemic and oral mucosal immunity is compromised by the residing tumour, 
antineoplastic treatment and by the recommended adjunctive treatment, thus leading to an 
imbalance and changes to the oral environment (De Sanctisa et al, 2016, Napeñas et al, 2010) 
and Donnelly et al, 2003).  
 
In addition to the cytotoxic effects of cancer treatment, factors such as neutropenia, 
xerostomia and the use of multiple drugs including antibiotics can affect this harmony. 
Patient-related factors such as the compromised oral hygiene, pre-existing periodontal disease 
and the presence of nosocomial pathogens can disrupt this delicate balance (Meurman et al., 
1997).  
 
When the bacterial flora is investigated in the presence of oral infection, the total number of 
commensal oral Streptococci is reduced with the colonization of opportunistic pathogens 
(Napeñas et al, 2010). This can be also observed in immunocompromised cancer patients 
with radiation-induced xerostomia, as higher counts of Streptococcus mutans, Lactobacillus 
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spp., Candida (mainly C. albicans) and Staphylococcus spp. have been found, whereas the 
number of S. sanguis, Neisseria spp. and Fusobacterium spp. has been shown to decline (De 
Ryck et al, 2015 and Brown et al, 1975). These changes allow for a higher prevalence of 
radiation-induced caries in these patients due to the poor saliva present, the altered pH and 
buffering capacity in saliva (Brown et al, 1975 and Almståhl et al 2001). The oropharyngeal 
mucosae is covered by a glycoprotein fibronectin that possesses attachment sites for gram 
positive microorganisms including S. pneumoniae, S. aureus and Actinomyces spp., whereas 
receptor sites for aerobic gram negative bacteria are thought to emerge after denudement of 
oral mucosae from fibronectin by the underlying disease (Yoneda et al, 2007). 
 
In a study done by Panghal et al, (2012), a predominance of gram positive bacteria (S. aureus 
and S. epidermidis) was found in the oropharynx and in the bloodstream of patients with 
varying grades of oral mucositis undergoing intensive chemotherapy and radiation. During 
the ulcerative phase of oral mucositis, bacterial translocation through the bloodstream may 
induce fever, infection and possible sepsis (Al-Dasooqi et al, 2013). These organisms could 
also enter into the bloodstream with the use of a central venous line (Panghal et al, 2012). 
Alteration in the microbiome has also been noted where proper sanitation is compromised in 
overcrowded hospitals or where oral and personal hygiene has been neglected (Panghal et al, 
2012). When oral pain is heightened to a degree that no alimentation is possible as seen in 
Grade IV oral mucositis, cancer patients have to be tube-fed and hence the emergence of 
other opportunistic gram positive pathogens such as Corynebacterium striatum and 
Streptococcus agalacticae (Renom et al, 2014). 
 
Moreover, immunocompromised patients undergoing antineoplastic chemotherapy, radiation 
and HSCT frequently develop infections arising from candida and have been associated with 
factors such as the immunosuppression of the host, the alteration of the oral microbiome and 
xerostomia (Naidu et al, 2004). The colonization of Candida spp. as seen in candidiasis and 
invasive candidemias, has been frequently seen in patients with neutropenia (Laheij et al, 
2012). As candidiasis can present clinically in its pseudomembranous and erythematous 
forms, patients with the erythematous forms complain of pain with or without a burning 
sensation and this can be confused with symptoms of oral mucositis (Jham and Freire, 2006). 
Although Candida albicans has been the most prevalent Candida species, non-albicans 
Candida species such as C. glabrata, C. krusei and C. dubliniensis have been identified in 
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radiation patients and patients undergoing HSCT (Laheij et al, 2012),  and studies has shown 
variations of certain species according to geographical locations (Jham and Freire, 2006, 
Ramla et al, 2016).  
 
Theories of an association between periodontitis and the severity of oral mucositis have been 
considered by Laheij et al, (2012) as they both have similar features of local and systemic 
inflammation and periodontal gram negative anaerobic bacteria have also been found in 
patients with oral mucositis. Evidence of this theory was disproved in a pilot study by Khaw 
et al, (2014) where even though a greater portion of patients with oral mucositis had 
periodontitis, this risk factor did not demonstrate any significance. Reports have shown that 
colonisation of bacteria in the ulcerative phase can enhance the severity of oral mucositis but 
evidence of antimicrobials failing to treat oral mucositis may prove that the microbial flora 
may not be the primary causative factor for this condition (Barasch et al, 2006 and Al-
Dasooqi et al, 2013). 
 
1.4.1 Cancer treatment and aerobic gram negative bacteria 
 
The presence of aerobic gram negative bacteria in the oral cavity is less frequently found in 
healthy individuals. The cells lining the oral cavity to the gastrointestinal tract are influenced 
by similar microbiological and immunological characteristics. This is illustrated by the 
presence of indigenous Escherichia coli in the gastrointestinal tract and the absence of 
aerobic gram negative bacteria in the oropharynx of healthy individuals. Individuals, who are 
carriers of Pseudomonas aeruginosa orally, are generally faecal carriers of the same strain 
(Leenstra et al, 1996). 
 
1.4.2 Factors associated with aerobic gram negative bacterial colonization and oral 
mucositis 
 
This colonization of gram negative organisms and the release of endotoxins in the ulcerative 
phase of oral mucositis occur on damaged mucosal tissue, which may be further complicated 
by concomitant neutropenia (Naidu et al, 2004).  Inflammatory mediators are released which 
influence the progression of oral mucositis (Köstler et al 2001).  
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Studies have demonstrated an overall increase in the prevalence of aerobic gram negative 
bacilli such as Escherichia coli, Pseudomonas aeruginosa, Klebsiella and Enterobacter spp. 
in cancer patients (Soares et al, 2011, Gaetti-Jardim et al, 2011 and Panghal et al, 2012). 
Panghal et al, (2012) describes that in developing countries like Lebanon, Malaysia and 
India, gram negative bacteria were the most predominant pathogen observed in febrile 
neutropenic patients. In a study done by Anirudhan et al, (2008) similar bacterial pathogens 
were found, but their blood culture showed bacterial sepsis due to the presence of 
Escherichia coli, Klebsiella and Enterococcus spp. In a systemic review by Napeñas et al, 
(2007) although paediatric cancer patients undergoing chemotherapy were more susceptible 
to gram positive oral bacteria such as Streptococci and Staphylococci, adult oncology patients 
were associated with changes involving gram negative bacteria such as Enterobacteriaceae 
and Pseudomonas spp.   
 
Similarly, bacterial translocation of aerobic gram negative bacteria, as described by Leenstra 
et al, (1996) can take place at the oropharynx and gastrointestinal tract regardless of presence 
of indigenous gram negative flora. Factors such as bacterial overgrowth, immunosuppression, 
and physical disruption of the gastrointestinal tract by cancer treatment, trauma and 
endotoxins are contributing factors of bacterial translocation (Jubelirer, 2011). 
 
1.4.2 Treatment associated with gram negative bacteria and oral mucositis 
 
Several suggestions have been made to prevent and treat oral mucositis by the reduction of 
the total bacterial count. The effect of PTA lozenges (Saunders et al, 2013 and Stokman et al, 
2003) and chlorhexidine gluconate may have eliminated selective oral flora but they were not 
efficacious in reducing the acute symptoms of oral mucositis (Wijers et al, 2001). In a study 
by Sano et al, (2015), various combinations of antibiotics such as ceftazidime plus 
piperacillin/tazobactum and ampicillin plus aztreonam, were some of the antibiotics that 
could be used. In a study by Baskaran et al, (2007) these antibiotics were also combined with 
an aminoglycoside and /or vancomycin for better results. The fact that most antibiotic 
interventions have failed, may suggest that other factors may be involved in the progression 




   
1.5 Endotoxins 
 
Gram negative aerobic and anaerobic bacteria possess endotoxins which are composed of 
lipopolysaccharides (LPS) found in the bacterial cell membrane (Leenstra et al, 1996). As 
these endotoxins are released, it may intensify the inflammatory process and promote or 
exacerbate ulcer formations in oral mucositis (Napeñas et al, 2007). Pathogens such as 
Escherichia coli, Pseudomonas and Vibrio cholerae have been associated with endotoxins. 
Routinely, in conjunction with the intestinal barrier, Kupffer cells in the liver can remove 
endotoxins by a process of detoxification and phagocytosis, but high prevalence of these 
endotoxins are seen in the systemic circulation if these cells cannot cope with the 
overwhelming burden of the presence of endotoxin (O'Brien and Bruce, 2007).  
 
In general, one endotoxin unit/ml (EU/ml) equals to 0.1ng/ml.   It has been reported that the 
normal endotoxin levels circulating in healthy individuals is between 0.3-10.4pg/ml (O'Brien 
and Bruce, 2007). In endotoxemia, plasma endotoxin concentrations are greater than 
2.5EU/ml or 0.25ng/ml (O'Brien and Bruce, 2007). There are recommendations for the 
allowable endotoxin limit for biological products, drugs and devices. According to the Food 
and Drug Administration (FDA 2012), water added to drugs that require dilution prior to 
injecting, sterile water for parenteral use and sterile, non-pyrogenic water for irrigation of 
body wounds or medical devices have an allowable endotoxin limit of 0.25 EU/ml. The 
maximum allowable endotoxin exposure for humans is calculated as 5 EU/Kg/Hour (or 350 
EU per adult for 70Kg person per hour) to avoid fever and hypotension from endotoxin 
contamination (FDA, 2012). For drugs gaining access to the cerebrospinal fluid (intrathecals), 
an endotoxin limit of 0.2 EU/Kg/Hour has been determined and 2.5 EU/Kg/Hour for 
radiopharmaceuticals (FDA, 2012). 
 
Endotoxin testing is crucial in establishing endotoxin limits for pharmaceutical and medical 
devices, in establishing procedures for validating the use of the bacterial endotoxin testing in 
the laboratory and establishing procedures for conducting routine testing. The Limulus 
Amebocyte Lysate (LAL) Test is utilized to test many drug and device products (FDA, 
2012). The most frequently used test is the LAL Chromogenic endpoint test which is a 
sensitive and specific test based on the chromogenic detection and measurement of 
endotoxin. 
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The lipopolysaccharide complex consists of three regions. The first region consists of O-
specific chains (O- antigens), which is known as the antibiotic-combining site affecting the 
immunogenicity of the pathogen cell wall. Diverse antigenic variations of the O side chains 
can occur between species and strains of pathogens as seen in Salmonella and E. coli and 
other strains of gram negative species. Absence of this region or parts of this region in E. coli 
and Salmonella allows for partial loss in virulence, making them susceptible to phagocytosis, 
serum bactericidal reactions, antibiotics and hydrophobic compounds as the permeability of 
the outer membrane is affected (Todar, 2002). 
 
The second component consists of the Core (R) antigen, which supports the LPS structure. It 
consists of various sugars including heptose which binds to 2-keto-3-deoxyoctonoic acid 
(KDO) (Koga et al, 1985). KDO is one of the sugars present in the Lipid A portion of LPS 
which is used as a positive index in investigating the presence of LPS. LPS from the 
Bacteroides species (anaerobic gram negative bacteria) lack composition of KDO and 
heptose (Leenstra et al, 1996). This region is less variable but they may not have identical 
cores (Todar, 2002). 
 
The Lipid A structure forms part of the third component of the LPS and affects the toxicity 
among Enterobacteriaceae. It is the least variable region (Peterson, 1996). They are 
associated with the toxicity of gram negative bacteria and when released in the circulation 
(Beveridge, 1999; Fry, 2013), are responsible for causing fever, diarrhoea, leukopenia, 
disseminated intravascular coagulation, hypotension and possible fatal endotoxic shock (Dey 
and Dey, 1978). Both Lipid A and the polysaccharide side chains determine the virulence of 
gram negative bacteria. They are liberated in large quantities only after the death, 
disintegration or autolysis of the organism (Dey and Dey, 1978). The endotoxicity of LPS for 
anaerobic gram negative bacteria such as Bacteroides species is much lower (1000 times less) 
than that of endotoxin from AGNB such as E.coli. This explanation can be justified by the 
course and outcome of septicaemia caused by Bacteroides species being more favourable 




   
LPS binds to lipid binding protein, which is associated with Toll-like receptor-4 (TLR4) for 
the recognition of the endotoxin in the host (Lundin and Checkoway, 2009). Endotoxic shock 
is the outcome as a result of the secretion of pro-inflammatory cytokines and nitric oxide by 
macrophages and endothelial cells. Several cytokines (IL-1, IL-6, IL-8 and TNF-α) and 
platelet- activating factor stimulate the production of prostaglandins and leukotriene, which 
are responsible for inflammation and septic shock. T-lymphocytes affect cell-mediated and 
humoral immunity and the complement cascade promotes histamine release leading to 
vasodilation. These patients are susceptible to blood clotting, thrombus formation and acute 
disseminated intravascular coagulation with the depletion of platelets and various clotting 
factors. Hypotension arises with the release of bradykinins and other vasoactive peptides. 
These sequences of events lead to inflammation, intravascular coagulation, haemorrhage and 
shock which is characteristic of endotoxemia (Lundin and Checkoway, 2009).  
 
The virulence and the rate of release of endotoxins are affected by variance in its biological 
activity, its potency between the different species and its pathogenic property among similar 
species. This may also be affected by host factors such as leukopenia (Hurley, 1995). On the 
contrary, if after the initial exposure to endotoxins, the body tolerates subsequent exposure of 
continuous small doses of LPS without adverse symptoms, this phenomenon is known as 
endotoxin tolerance (Lundin and Checkoway, 2009). 
 
The control of endotoxin absorption is crucial at the oropharynx and gastrointestinal tract. 
Neutralization of endotoxin occurs with the macrophages and lymphoid tissue in these 
tissues. Endotoxins that enter into the systemic circulation are neutralized by platelets, 
proteins and leucocytes in blood. Intraorally, the action of swallowing, reflex movements, 
tongue movement, salivary flow and salivary mucins affect the clearance of aerobic gram 
negative bacteria and endotoxin. Gastric motility and bile are important for the removal of 
endotoxins in the gastrointestinal tract (Leenstra et al, 1996). Bacterial translocation of 
aerobic gram negative bacteria can occur regardless of the presence of indigenous gram 
negative flora which elevates the LPS concentration systemically and attributes towards the 
high endotoxicity (Leenstra et al, 1996).  
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1.5.1 Endotoxins and oral mucositis 
Although the involvement of endotoxins in the development of bacterial infections is well 
described, the role of endotoxins in oral mucositis is not known. Cancer patients develop oral 
mucositis due to the cytotoxicity of chemotherapy and the changes in the oral flora with the 
alteration in the oral environment. The abnormal presence of aerobic gram negative bacteria 
which produce endotoxins, has also been reported, which interact with the host's cells to 
induce the production and secretion of proteases and pro-inflammatory cytokines (Gaetti-
Jardim et al, 2011 and Ramachandran, 2014). Nevertheless, the role of these endotoxins in 




The aim of this study was to isolate and identify all aerobic gram negative bacteria and 
endotoxins in the oral cavities of patients receiving cancer treatment; and to determine 
whether the concentration levels of endotoxins affect the severity of oral mucositis within its 
various grades. 
 
1.6.1 Study Objectives 
 To isolate Streptococci, Staphylococcus aureus, Candida species and aerobic 
gram negative bacteria (AGNB) from the oral cavities of patients on cancer 
treatment and healthy individuals. 
 To identify all the aerobic gram negative bacteria and perform antimicrobial 
susceptibility tests. 






   
CHAPTER 2 
METHODS AND MATERIALS 
2 Study population  
 
A cross-sectional study was done on patients diagnosed with any type of malignant solid 
tumor, who were scheduled for either radiation and chemotherapy or only chemotherapy that 
were attending clinics at the Department of Radiation Oncology and the Department of 
Oncology, at the Charlotte Maxeke Johannesburg Academic Hospital, were approached and 
asked to volunteer for the study.  
A sample size of one hundred cancer patients was determined, based on previous studies on 
cancer patients undergoing treatment (Panghal et al, 2012 and Anirudhan et al, 2008), and 
studies done on the presence of gram negative bacteria in healthy individuals who smoked or 
wore dentures (Conti et al, 2009). In both studies a large sample size was required, as the 
percentage of gram negative bacteria isolated were lower in proportion as compared to other 
bacterial isolates.  
 
2.1 Exclusion and inclusion criteria 
These patients were chosen based on the criteria as per the data collection sheet (Appendix 
B). The exclusion criteria included HIV positive patients, diabetic patients, smokers and 
patients who wore oral prostheses. Patients who were presently on antimicrobials and patients 
who had less than 2 weeks of cancer treatment were also not eligible to participate in the 
study. At the time of sampling, the procedure was explained to the selected patients and 
written consent was obtained (Appendix A and B). The demographic data and clinical 
parameters such as the type of cancer, type treatment and duration of treatment were 
recorded. The presence or absence and the grade of oral mucositis (WHO, 1979), was 
observed by inspecting their oral cavity. Oral observation, periodontal and caries screening 
procedures were used to detect halitosis, periodontitis, dry mouth and dental caries. Eligible 
patients were asked to rinse their oral cavity with 10 ml of sterile distilled water and this was 
collected back into a sputum jar. All samples collected were processed at the Oral 
Microbiology Laboratory. 
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A sample size of fifty healthy individuals over the age 18 years old and of either gender  from 
the Oral Biological Sciences Department and Wits Oral Health Department, was used as a 
control group and chosen as per the criteria from the data collection sheet (Appendix A and 
B). The exclusion criteria included individuals who did have any systemic diseases (such as 
diabetes), smokers, those who wore oral prostheses and individuals who were presently on 
antimicrobials.  Similarly, an oral rinse was collected from the control group. All samples 
that were collected were processed at the Oral Microbiology Laboratory. 
 
2.2 Ethics  
 
Ethical clearance (Certificate number: M160562) for the study was obtained from The 
Committee for Research on Human Subjects (Medical), University of the Witwatersrand, 
Johannesburg (Appendix C).  
 
2.3 Microbiological analysis  
2.3.1 Microbiological plating procedure 
 
Media preparation procedures are described in Appendix D. 
 
The oral cavity rinse samples were vortexed and one hundred microlitres of this sample was 
serially diluted in 0.9ml of phosphate buffered saline and mixed using a vortex mixer to 
create dilutions of 1/10 to 1/1000.  One hundred microlitres of the oral rinse and the 
respective serially diluted saliva were plated using an air displacement micropipette with 
disposable pipette tips on Mitis Salivarius Agar (MSA), Baird Parker Agar (BP), Candida 
Chromagar and MacConkey Agar (Figure 2.1). In addition, 0.5 ml of oral rinse was added 
into Brain Heart Infusion broth (BHI) and this was incubated at 37
o
C for 24 hours as an 
enrichment step to allow low numbers of aerobic gram negative bacteria to be detected 
(Stokman et al, 2003). The Mitis Salivarius Agar plates were incubated at 37
o
C for 48 hours 
under CO2 to isolate Streptococci.  The Baird Parker Agar plates (to isolate Staphylococci), 
the Candida Chromagar plates (to isolate Candida) and the MacConkey Agar plates (to 
isolate aerobic gram negative bacteria) were incubated at 37
o
C for 48 hours aerobically. After 
the incubation period, the colonies were manually counted and expressed as colony forming 
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unit/ml (cfu/ml), similar to a study that was done by Ahmed et al (2013).  One millilitre of 
oral rinse from all cancer patients and healthy individuals were labelled and stored in 
Eppendorff tubes at -20
o
C for the endotoxin assay. 
 
 
Figure 2.1: Layout of agar plates for the microbiological analysis 
 
2.3.2 Colony counts 
Blue colonies were counted (cfu/ml) to obtain the total bacterial count of Streptococcus 
mutans on the Mitis Salivarius Agar plate (Figure 2.2). Counts were multiplied with the 
dilution factors and expressed as counts per ml of oral rinse. 
 
Figure 2.2: Colonies of Streptococcus mutans on a Mitis Salivarius Agar plate 








   
Black colonies with a halo around the colony were counted to obtain the total bacterial count 
of Staphylococcus aureus (cfu/ml) from the Baird Parker Agar plate (Figure 2.3).  
 
 
Figure 2.3: Colonies of Staphylococcus aureus on a Baird Parker Agar plate 
 
Green, purple and blue colonies of Candida species were counted (cfu/ml) on the Candida 
Chromagar plates (Figure 2.4). 
 
Figure 2.4: Mixed culture of Candida species on a Chromagar plate 
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The light and dark pink colonies of aerobic gram negative bacteria were counted (cfu/ml) 
from the MacConkey Agar plates. After incubation, the BHI broth showed turbidity from the 
growth of microorganisms. This was sub-cultured on MacConkey Agar plates and incubated 
at 37
o
C for a further 48 hours by the streaking technique using a cooled sterilized loop. The 
Gram staining technique was preliminary performed on certain isolated colonies, similar to a 
technique described in a study by Ahmed et al, (2003) to identify the presence of gram 
positive and gram negative cocci and bacilli. 
 
         
Figure 2.5 Plate A and B: Colonies of aerobic gram negative bacteria on a MacConkey 
Agar plate 
                   
2.3.3 The isolation and identification of Candida spp. 
An isolated colony of Candida spp. from the Chromagar was randomly selected and plated 
using the streaking technique. A cooled sterilized loop was used to streak a Sabouraud Agar 
plate, which was used as an isolation plate and incubated for a further 48 hours at 37°C 
(Figure 2.6). These cultures were then identified using the API® 20 C AUX (bioMérieux) 
system. All the different colour colonies were isolated and identified separately. 
 
Plate A Plate B 
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Figure 2.6: Isolated colonies of Candida spp. on Sabouraud agar 
 
The API® 20 C AUX system was used for the precise identification of C. albicans and other 
yeasts that were encountered which was similarly also used in a study by Ahmed et al, 
(2013). The API® 20 C AUX strip consists of 20 cupules (Table 2.1), containing dehydrated 
substrates which enable the performance of 19 assimilation tests. A suspension constituting 
of a young culture of a portion of a well isolated yeast colony from the isolation Sabouraud 
Agar plate and 2ml of the API C Medium, was mixed with turbidity equal to 2 McFarland 
standard. This is done to standardize the turbidity of the yeast solution tested by obtaining a 
solution with a specific optical density. 
 
This was used to inoculate the cupules using a Pasteur pipette. The strips were tilted forward 
and the Pasteur pipette was placed against the side of the cupule to prevent the formation of 
air bubbles at the base of the tubes and care was taken not to overfill and underfill the 
cupules. The yeasts only grew if they were capable of utilizing each substrate as their sole 
carbon source. After 48 and 72 hours of incubation at 37°C, growth was read by comparing 
its turbidity to growth controls (Figure 2.7).  Identification was obtained by referring to the 





   
Table 2.1:   Contents of the cupules of the API® 20 C tray 
Tests Active Ingredients Quantity(mg/cup) 
0 None - 
GLU D-GLUcose 1.2 
GLY GLYcerol 1.2 
2KG Calcium 2-Keto-Gluconate 1.2 
ARA L-ARAbinose 1.2 
XYL D-XYLose 1.2 
ADO ADOnitol 1.2 
XLT XyLiTol 1.2 
GAL D-GALactose 1.9 
INO INOsitol 2.36 




NAG N-Acetyl-Glucosamine 1.2 
CEL D-CELlobiose 1.2 
LAC D-LACtose (bovine origin) 1.2 
MAL D-MALtose 1.2 
SAC D-SACcharose (sucrose) 1.2 
TRE D-TREhalose 1.2 
MLZ D-MeLeZitose 1.2 
RAF D-RAFfinose 1.9 
 
 
Figure 2.7: API® 20 C AUX system for the identification of Candida species. 
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2.3.4 The isolation and identification of aerobic gram negative bacteria 
On each MacConkey Agar plate where growth of aerobic gram negative bacteria had been 
found from cancer patients and healthy subjects, isolated colonies of this bacteria were 
randomly selected and plated using a cooled sterilized loop onto another MacConkey Agar 
plate and incubated for 48 hours at 37°C (Figure 2.8). 
 
    
 
 







   
An oxidase test was performed to determine the presence of the bacterial cytochrome oxidase 
enzyme by using the wet filter paper method, similarly, as performed in a study by Ahmed et 
al, (2003). Using a sterile cool loop, a small portion of a pure colony was transferred onto a 
filter paper saturated with oxidase reagent and rubbed onto the reagent. A positive reaction 
was indicated by an intense deep-purple hue within 10- 30 seconds. A negative test resulted 
in a light-pink or absence of colouration (Figure 2.9). 
 
Figure 2.9: Oxidase Test for the aerobic gram negative bacteria 
 
These cultures were identified using the API® 20 E (bioMérieux) system. This system was 
similarly used in a study by Conti et al, (2009) to identify Enterobacteriaceae on the dorsum 
of the tongue and a study by Leenstra et al, (1996) in the identification of gram negative 
aerobic bacteria. It consists of 20 microtubes containing dehydrated chromogenic substrates. 
A bacterial suspension consisting of a well isolated colony from the isolation MacConkey 
Agar plate was added to 5ml of sterile distilled water without additives and emulsified. The 
tests were inoculated with the bacterial suspension using a Pasteur pipette, tilting the strips 
forward and placing the Pasteur pipette against the side of the cupule to prevent the formation 
of air bubbles at the base of the tubes. They were incubated at 37
o
C for 24 hours. Colour 
changes occurred either spontaneously during incubation from metabolism or after the 
addition of reagents after the incubation period (Figure 2.10). These reactions were read 
according to the Reading Table and the identification was obtained by referring to the 





   
 
Figure 2.10: API® 20 E System for the identification of aerobic gram negative bacteria 
 
Table2.2: Reading Table: API® 20E System (Adapted from API® 20E System reading manual) 
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2.4 Antibiotic Sensitivity Test 
 
The inoculum was prepared by making a saline suspension of young culture of isolated colonies 
from the MacConkey Agar plate of cancer patients and healthy individuals with a positive 
identification for aerobic gram negative bacteria. The suspension was adjusted to match the 0.5 
McFarland turbidity standard, using a spectrophotometer at an absorbance of 625nm.  
 
The surface of a Müeller-Hinton agar plate was inoculated by streaking a sterile buccal swab 
over the entire agar surface of three agar plates per sample. This procedure was repeated by 
streaking two more times, rotating the plate approximately 60 each time to ensure an even 
distribution of inoculum.  As a final step, the rim of the agar was swabbed. Each of the three 
different labelled agar plates received six different commercially-prepared, fixed concentration 
paper antibiotic discs, which were placed evenly and distributed on the inoculated agar 
surface by a disc dispenser. The plates were incubated at 37
o
C for 24 hours. The plates were 
read after 24 hours using transmitted light by looking for any growth within the zone of 
inhibition. The susceptibility patterns were noted. 
 
The zones of growth and inhibition around each of the antibiotic discs were measured to the 
nearest millimetre using sliding callipers (Figure 2.11). The diameter of the zone was related 
to the susceptibility of the isolate and to the diffusion rate of the drug through the agar 
medium. The zone diameters of each drug were interpreted using the criteria published by the 
Clinical and Laboratory Standards Institute (CLSI, 2016). The qualitative results were based 
on the category of susceptibility, namely Susceptible (S), Intermediate (I), or Resistant (R) to 
the agents. The antibiotic discs on agar plate one (N1) had 10µg Ampicillin, 30µg 
Cefotaxime, 30µg Cefuroxime, 30µg Cefoxitin, 10µg Piperacillin-tazobactam and 10µg 
Gentamicin. Agar plate two (N2) contained 30µg Cefepime, 10µg Ertapenem, 10µg 
Imipenem, 10µg Meropenem, 30µg Ceftazidime and 10µg Amoxicillin- clavulanate. Agar 
plate three (N3) contained 30µg Nalidixic, 10µg Tobramycin, 30µg Amikacin, 30µg 






   
   
 
 
        Figure 2.11: Antibiotic Susceptibility Test on Müeller-Hinton Agar plate 
                               
2.5 Endotoxin assay 
 
The Hycult Biotech Limulus Amebocyte Lysate (LAL) assay was used to detect endotoxins 
in the oral rinse samples collected from 60 cancer patients and 16 healthy individuals. The 
oral rinse samples analysed from cancer patients were with or without aerobic gram negative 
bacteria and with or without oral mucositis. The oral rinse samples analysed from healthy 
individuals did not present with aerobic gram negative bacteria. This assay can measure the 
bacterial endotoxin in gram negative bacteria from various biological fluid (including sera), 
devices, (air) filters and tissue culture medium. It is a sensitive product that detects from as 
little as 0.04 EU/ml of endotoxin and ranges to 10 EU/ml. It is a specific and accurate product 





   
The basis of this test was that these bacteria caused intravascular coagulation in the American 
horseshoe crab, Limulus Polyphemus by endotoxin, triggering the turbidity and gel-forming 
reaction enzymatically. The enzymatic reaction of this test will cause a yellow colour to 
develop upon cleavage of chromophore, p-nitroaniline (pNA), which is stopped by the 
addition of acetic acid as a stop solution. The absorbance at 405 nm is measured with a 
spectrophotometer. The endotoxin concentration of samples with unknown concentrations, 
which are run concurrently with the standards, can be determined from a standard curve. It 
uses an endotoxin standard of known concentration that is derived from the E. coli strain as 
stated on the Certificate of Analysis to create a standard curve. The developed colour 
intensity is proportional to the amount of endotoxin present in the sample and its 
concentration is determined by extrapolating the absorbance of an unknown sample against 
this standard curve.  
 
The oral rinse that was stored at -20ºC in the Eppendorff tubes were warmed back to room 
temperature. Samples were centrifuged at 5000 rpm for 5 minutes, similar to a method 
described by Leenstra et al, (1996). The supernatants were collected (200μl) into another 
Eppendorff tube. These were placed on a heating block at 75ºC for 5 minutes to neutralize 
any endotoxin inhibiting compounds. From each sample of oral rinse, 25μl was diluted with 
175μl of endotoxin free water (EFW) from the Hycult Biotech Limulus Amebocyte Lysate 
(LAL) assay kit to give a dilution of 1:8. 
 
All materials in contact with the oral rinse such as pipette tips, the test material and its 
contents and reagents were endotoxin free. Depyrogenated test tubes were also utilized. All 
reagents were equilibrated to room temperature at 25°C. 
 
The LAL reagent was prepared by adding 4ml of EFW to the LAL reagent vial. This was 
gently swirled until the LAL reagent dissolved into a colourless solution. The standard 
solution was reconstituted by pipetting 1.8ml of EFW (as stated on the Certificate of 
Analysis) to the concentrated endotoxin (E. coli) standard (Lot number 19819K0316-A), to 
give a concentration of 50 EU/ml after reconstitution. This was vortexed for 5 minutes. The 




   
The number of test wells required to assay the standards, controls and samples in duplicate 
was determined and labelled accordingly. For the standard series, 50μl of the reconstituted 
standard was added to 50μl of EFW using a calibrated micropipette, and vortexed for 30 
seconds, to dilute it further to obtain a concentration of 25 EU/ml (Figure 2.12). For the 
duplicate standard curve, 16 wells of the plate were filled with 50μl of EFW. Thereafter, 33μl 
of the diluted standard was added to well A1 and diluted 1:1.5 further and mixed thoroughly. 
This was repeated by pipetting 33μl of this over to well B1 and again to the next well and so 
on until well number G1. From well G1, 33μl was discarded and well H1 was used as a 
control. This procedure was repeated for the standard dilution method for the A2-H2. This 
gave a concentration range of endotoxin as follows: 10, 4, 1.6, 0.64, 0.26, 0.10, and 0.04 
EU/ml. 
 
From each of the diluted samples, 50μl was transferred in duplicate to the assigned sample 
and control wells with a clean pipette for each transfer done. From the reconstituted LAL 
reagent, 50μl was added to each well, except in the control wells, where 50μl of EFW was 
added instead of LAL reagent. The plate was covered and incubated for 30 minutes at room 
temperature. The enzymatic reaction, triggered by endotoxin, caused a yellow colour to 
develop upon cleavage of the chromophore, p-nitroaniline. The samples were measured at 
405nm using a calibrated ELISA plate reader (spectrophotometer). Similarly samples were 
processed (Figure 2.13). 
 
If the standard concentrations between 10 and 4 EU/ml differed more than 10% in OD value, 
this was incubated for an additional 5 minutes. If it differed less than 10% in OD value, the 
reaction was halted by adding 50μl of stop solution. The absorbance was measured at 405nm 











   
 
Figure 2.12: Preparation of the dilutions of standard series of E. coli endotoxin 
Adapted from Limulus Amebocyte Chromogenic Endpoint Assay: Test for endotoxin 
detection- Product information and manual.  Manual HIT302 Edition 04-13 
  
 
If individual absorbance values differed by more than 15% from the corresponding mean 
value, the sample was retested. The mean absorbance of the zero standard should be less than 
0.1 OD 405nm and the mean absorbance of the 10 EU/ml standard should be higher than 0.6 
OD 405nm. A standard curve was obtained by plotting the absorbance (linear) versus the 
corresponding concentrations of the E. coli standards (log). The endotoxin concentration of 
the samples was read from the standard curve and this was multiplied by the dilution factor 












Figure 2.13 The assigned wells for the standard series, samples and controls 
 
2.6 Statistical analysis of the data 
The data was sorted and cleaned (identification, diagnosing and removal of missing 
variables). The data was imported into Statistica 12 for analysis. Results showed that by using 
the Shapiro Wilk test, there was no normality in the distribution in counts of S. aureus, 
Streptococci, Candida and endotoxin between the different study groups (p>0.05). Thus, the 
median and interquartile ranges were reported as measures of central tendency and the 
statistical significance was determined by using the Mann-Whitney test. The carrier rate 
between the different populations was computed on frequency tables of percentages and the 
chi-square test was used to check the statistical significance in the differences in percentage. 





    +ve Controls                               Samples 
    -ve Controls                               Samples 
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CHAPTER 3 
RESULTS 
3.1 Demographic data and clinical parameters 
Demographic data and clinical parameters of cancer patients on treatment are shown in Table 
3.1. The mean age of cancer patients was 52 years and 80% of cancer patients were females. 
These females mostly had either breast (58%) or cervical cancer (9%). Majority of these 
patients were on chemotherapy (61%). Patients were well into their chemotherapy treatment 
cycles and were on multiple chemotherapeutic drugs. The majority of them complained of 
nausea (61%). Most of them had no major other illness except for hypertension (21%). Some 
patients had oral mucositis (12%) which was classified as Grade I, Grade II, Grade III and 
Grade IV. Patients complained of dry mouth, altered taste and loss of appetite. 
 
Table 3.1: Demographic data and clinical parameters of cancer patients on treatment  
Parameters (n=100) Results 
Age 
Mean ±SD (Range) 
 
51.87 ± 12.8 (25-92) 
Gender Male:     20%, Female: 80% 
Type of Cancer 
 
Breast cancer: 58%, Cervical cancer: 9%, Prostate cancer: 
6%, Colon cancer: 5%, Rectal cancer: 4%, Laryngeal cancer: 
3%, Pancreatic cancer: 2%, Skin cancer: 2%,  
Bone cancer, Brain cancer, Colon and Liver cancer, Gastric 
cancer, Liver cancer, Lung cancer, Nasal cancer, Ovarian cancer, 
Ovarian, Intestine, Liver, Vulva cancer, Palatal cancer, Spleen 




Chemoradiation: 39%, Chemotherapy: 61% 
Length of treatment 
completed 
 
Chemoradiation: (n= 39) 
a. Chemotherapy cycles Mean ±SD (Range): 5.41 ±3.4 (2-14)  
 
b. Radiation sessions Mean ±SD (Range): 15.82 ±10.8 (1-35)  
 
Chemotherapy: (n= 61) 











   
Adriamycin + Cyclophosphamide + Taxol: 6% 
5 Fluorouracil + Leucovorin + Calcium: 5% 
5 Fluorouracil + Adriamycin + Cyclophosphamide: 5% 
5 Fluorouracil: 2% 
Adriamycin + Cyclophosphamide + Docetaxel: 2% 
Adriamycin, Adriamycin + Cyclophosphamide + Doxorubicin,  
Adriamycin + Cyclophosphamide + Tamoxifen, Cisplatin + 
Decadron, Docetaxel, Docetaxel + Decadron + Prednisone, 
Gemzar, Navelbine, Tamoxifen, Trial Chemo Drug, Xeloda + 




Nausea & Vomiting Yes: 61%, No: 39% 
Diabetes No: 100% 





High blood pressure: 21% 
 
Asthma, Cholesterol, Depression, arthritis, Blood Clotting, 
thyroid condition, Stomach Ulcers: 1% each 
 
Smoker No: 100% 
Dentures No: 100% 
Antimicrobials No: 100% 
Oral Mucositis 
 
History of oral mucositis: 27% 
Oral mucositis present: 12% 
None present or no history: 61% 
 
Grade of oral mucositis 
 
Grade 0: 69%,    Grade I: 16%,   Grade II: 11% 
Grade III: 3%,   Grade IV: 1% 
Loss of appetite Yes: 57%, No: 43% 
Difficulty to swallow Yes: 33%, No: 67% 
Altered taste Yes: 74%, No: 26% 
Halitosis Yes: 22%, No: 78% 
Swollen gums Yes: 24%, No: 76% 
Periodontitis Yes: 42%, No: 58% 
Dry mouth Yes: 88%, No: 12% 








   
3.2 Demographic data and clinical parameters of healthy individuals 
Demographic data and clinical parameters of healthy individuals are shown in Table 3.2.  The 
mean age of this study group was 31 years and they were mainly females (76%). They were 
relatively healthy with no illnesses (94%) and their oral health was also relatively good. 
 
Table 3.2: Demographic data and clinical parameters of healthy individuals  
Parameters (n=50) Results 
Age Mean ±SD (Range) 30.50 ± 11.6 (19-57) 
Gender Male: 24%, Female: 76% 
Diabetes No: 100% 
Other systemic diseases 
 
High blood pressure: 6%, Hypothyroidism: 2% 
None: 94% 
Smoker No= 100% 
Dentures No= 100% 
Antimicrobials No= 100% 
Halitosis No= 100% 
Swollen gums Yes: 16%, No: 80% 
Periodontitis Yes: 2%, No: 98% 
Dry Mouth Yes: 16%, No: 84% 
Dental caries Yes:  34%, No: 66% 
 
3.3 Microbiological analysis of oral rinse samples collected from the cancer patients 
on treatment  
The raw data of the microbiological analysis, endotoxin and the statistical analysis are 
presented in Appendix E, F and G. 
 
The results of the microbiological analysis of oral rinse samples collected from the cancer 
patients on treatment are shown in Table 3.3. All the patients carried Streptococcus species in 
their oral cavity and the mean counts were 2.1 x 10
6
 cfu/ml. Staphylococcus aureus and 
Candida species was carried by 52% and 54% of patients respectively. The mean S. aureus 
counts (1939 cfu/ml) were much higher than the Candida counts (693 cfu/ml). These cancer 
patients carried multiple species of Candida. The major species carried was C. albicans, 
followed by C. glabrata and C. famata. Six patients carried more than one species of 
Candida. Twenty four percent of patients carried aerobic gram negative bacteria in their oral 
cavity. Counts of these bacteria were not possible because some of them were identified after 
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the enrichment technique. Eleven different types of gram negative bacteria were identified 
and the most isolated bacteria were Enterobacter cloacae. 
Table 3.3: Microbiological analysis of oral rinse samples collected from cancer patients 
on treatment  
Organism Carriage 
(%) 
Counts in carriers 
cfu/ml  
Mean ±SD (range) 
Identification 
(no. of isolates) 
Streptococcus 
species  
100 2142950 ± 3274759.1 
(87000 - 24880000)  
Not done 
 
S. aureus  
  
52 1938.90 ± 4705.9 
(10-15000) 











54 692.59 ± 1732.5 
(10- 10000)  
 
 
Candida albicans (44) 
Candida glabrata (9) 
Candida famata (5)  




[C. albicans + C. glabrata (6)]  
[C. albicans + S. cerevisiae (1)] 
 




24 Not done Enterobacter cloacae (6) 
Escherichia coli (4) 
Klebsiella pneumonia (3)  
Pantoea Spp.(2) 
Pseudomonas aeruginosa (3) 
Aeromonas hydrophila (1) 
Klebsiella oxytoca (1) 
Citrobacter koseri (1) 
Serratia rubidaea (1) 
Kluyvera spp. (1) 
Pasteurella pneumotropica (1) 
 
 
3.4 Antimicrobial susceptibility of aerobic gram negative bacteria isolated from the 
oral cavities of cancer patients on treatment 
The results of the antimicrobial susceptibility of aerobic gram negative bacteria isolated from 
the oral cavities of cancer patients on treatment are shown in Table 3.4. The data was very 
small to interpret, however resistance to antibiotics was high in Pseudomonas species.  
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Table 3.4 Antimicrobial susceptibility of aerobic gram negative bacteria isolated from the oral cavities of cancer patients on treatment 
 





































AP 1 (16.66) 3 (75) 3 (75) 2 (66.66) 0 1(100) 0 0 0 1 (100) 11 (45.83) 
CTX 0 1 (25) 0 2 (66.66) 0 0 0 0 1 (100) 0 4 (16.66) 
CXM 0 1 (25) 0 2 (66.66) 0 0 0 0 1 (100) 0 4 (16.66) 
FOX 4 (66.66) 0 0 2 (66.66) 0 0 0 0 0 0 6 (25) 
PTZ 1 (16.66) 0 1 (25) 0 0 0 0 0 0 0 2 (8.33) 
GM 0 0 1 (25) 0 1 (50) 0 0 0 0 0 2 (8.33) 
CPM 0 0 0 1 (33.33) 0 0 0 0 1 (100) 0 2 (8.33) 
ETP 0 0 0 1 (33.33) 0 0 1 (100) 0 0 0 2 (8.33) 
IMI 0 0 0 0 0 0 0 0 0 0 0 
MEM 0 0 0 0 N/D 0 0 0 N/D 0 0 
CAZ 1 (16.66) 0 0 1 (33.33) 2 (100) 0 0 0 1 (100) 0 5 (20.83) 
AUG 2 (33.33) 1 (25) 1 (25) 2 (66.66) 0 0 0 0 0 0 6 (25) 
NA 1 (16.66) 0 2 (50) 2 (66.66) 2 (100) 0 0 1 (100) 1 (100) 0 9 (37.5) 
TN 0 1 (25) 1 (25) 0 1 (50) N/D 1 (100) 0 0 0 4 (16.66) 
AK 0 0 0 0 0 0 0 0 0 0 0 
C 0 1 (25) 0 1 (33.33) 0 0 0 0 1 (100) 0 3 (12.5) 
TS 0 2 (50) 3 (75) 0 0 0 0 0 0 0 5(20.83) 
CIP 0 1 (25) 1 (25) 0 0 0 0 0 0 0 2 (8.33) 
Ab = Antibiotic, N/D = Not done,  AP = Ampicillin, CTX = Cefotaxime, CXM = Cefuroxime, FOX = Cefoxitin, PTZ = Piperacillin-tazobactam, GM = 
Gentamycin, CPM = Cefepime, ETP = Ertapenem, IMI = Imipenem, MEM = Meropenem, CAZ = Ceftazidime, AUG = Amoxicillin- clavulanate potassium, 








   
3.5 Microbiological analysis of oral rinse samples collected from healthy individuals 
 
The results of the microbiological analysis of oral rinse samples collected from healthy 
individuals are shown in Table 3.5. Ninety eight percent of individuals carried Streptococcus 
species in their oral cavity and the mean counts were 1.1 x 10
6
 cfu/ml. Staphylococcus aureus 
and Candida species was carried by 36% and 20% of individuals respectively. Mean S. 
aureus counts were 433 cfu/ml whereas the Candida counts were 1149 cfu/ml. These healthy 
individuals also carried more than one species of Candida. The major species carried was C. 
albicans. Fourteen percent of patients carried aerobic gram negative bacteria in their oral 
cavity. Counts of these bacteria were not possible because some of them were identified after 
the enrichment technique. Three different types of gram negative bacteria were identified and 
the most isolated bacteria were Enterobacter cloacae. 
 





Counts in carriers cfu/ml  
Mean ±SD (range) 
Identification 
(no. of isolates) 
Streptococcus 
species  
98 1144616.33 ± 1110205.0  
(1200 - 4600000)  
Not done 
 
S. aureus count  36 433.33 ± 1210.2 
(10 - 4700)  
S. aureus (52) 
 
Candida species 20 1149 ± 2353.5 
(10 - 6000)  
Candida albicans (7) 
Candida famata (1) 
Candida dubliniesis (1) 
Candida krusei (1) 
Aerobic gram 
negative bacteria 
14 Not done Enterobacter cloacae (3) 
Klebsiella oxytoca (1) 








   
3.6 Antimicrobial susceptibility of aerobic gram negative bacteria isolated from the 
oral cavities of healthy individuals 
 
The results of the antimicrobial susceptibility of aerobic gram negative bacteria isolated from 
the oral cavities of healthy individuals are shown in Table 3.6. Klebsiella species was found 
to be resistant to many antibiotics.  
 
Table 3.6: Antimicrobial susceptibility of aerobic gram negative bacteria isolated from 
the oral cavities of healthy individuals 
 










AP 0 4 (100) 4 (66.66) 
CTX 0 2 (50) 2 (33.33) 
CXM 0 2 (50) 2 (33.33) 
FOX 2 (100) 2 (50) 4 (66.66) 
PTZ 0 0 0 
GM 0 2 (50) 2 (33.33) 
CPM 0 0 0 
ETP 0 0 0 
IMI 1 (50) 0 1 (16.66) 
MEM 0 0 0 
CAZ 0 2 (50) 2 (33.33) 
AUG 1 (50) 0 1 (16.66) 
NA 0 2 (50) 2 (33.33) 
TN 0 2 (50) 2 (33.33) 
AK 0 0 0 
C 0 2 (50) 2 (33.33) 
TS 0 1 (25) 1 (16.66) 
CIP 0 0 0 
Ab = Antibiotic, AP = Ampicillin, CTX = Cefotaxime, CXM = Cefuroxime, FOX = Cefoxitin, PTZ = 
Piperacillin-tazobactam, GM = Gentamycin, CPM = Cefepime,  
ETP = Ertapenem, IMI = Imipenem, MEM = Meropenem, CAZ = Ceftazidime, AUG = Amoxicillin- 
clavulanate potassium, NA = Nalidixic acid, TN= Tobramycin, 







   
3.7 Summary results of cancer patients and healthy individuals 
 
Summary results of cancer patients and healthy individuals are shown in Table 3.7 and Figure 
3.1. Cancer patients carried significantly high numbers of Streptococci compared to the 
healthy individuals. The carriage rate of S. aureus was not different between the two groups. 
The results also showed that the Candida carrier rate was significantly high in cancer patients 
compared to healthy individuals (p<0.01). Although the Candida counts were not different 
between the groups (p>0.05), cancer patients carried a variety of Candida species and some 
patients carried more than one Candida species in their oral cavity. In addition, C. glabrata 
was only found in cancer patients. Between the two groups, no significant difference in the 
carrier rate of aerobic gram negative bacteria was found (p>0.05). However, cancer patients 
carried a variety of aerobic gram negative bacteria. Enterobacter cloacae and Klebsiella 
pneumonia were isolated from the oral cavities of both the study groups.  
 
Table 3.7: Summary results of cancer patients and healthy individuals 
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C. albicans (44) 
C. glabrata (9) 
C. famata (5)  






1149 ± 2353.5 
(10 - 6000) 
 
 
C. albicans (7) 
C. famata (1) 
C. dubliniesis (1) 
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E. cloacae (3) 
K. oxytoca (1) 







     
 
Figure 3.1 Prevalence of S. aureus, Candida species and aerobic gram negative bacteria 
























   
3.8 S. aureus, Candida species and aerobic gram negative bacteria (AGNB) in cancer 
patients with and without oral mucositis  
The results of S. aureus, Candida species and aerobic gram negative bacteria (AGNB) in 
cancer patients with and without oral mucositis are shown in Table 3.8 and Figure 3.2. The 
results showed that the prevalence of S. aureus and the counts were not significantly different 
in patients with oral mucositis and patients without oral mucositis. Similarly percentage 
prevalence of aerobic gram negative bacteria was also similar in both study groups. However, 
percentage prevalence of Candida species was significantly high in patients with oral 
mucositis compared to the patients without oral mucositis. 
Table 3.8: Presence of S. aureus, Candida species and aerobic gram negative bacteria 
(AGNB) in cancer patients with and without oral mucositis  







S. aureus Prevalence (%) 7 (58.3) 45 (51.13) p >0.05 
Mean counts 
(cfu/ml) 
159.7 2215.7 p >0.05 
Candida species Prevalence (%) 9 (75) 47 (53.4) p <0.01 
Mean counts 
(cfu/ml) 
1021.1 616.35 p >0.05 
AGNB Prevalence (%) 4 (33.3) 20 (22.7) p >0.05 
 
 
Figure 3.2 Prevalence of S. aureus, Candida species and aerobic gram negative 
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3.9 Endotoxin in the oral rinse samples of cancer patients and healthy individuals 
The results of the endotoxin in the oral rinse samples of cancer patients and healthy 
individuals are shown in Table 3.9 and Figure 3.3. The range of endotoxins detected was 
1.35ng/ml to 8.2ng/ml. In the oral rinse samples of cancer patients and healthy individuals, 
the mean endotoxin concentration of 3.65ng/ml and 3.37ng/ml was found respectively. The 
difference in the endotoxin between the two groups was not significant (p=0.5).  
Table 3.9: Presence of endotoxin in the oral rinse samples of cancer patients on 
treatment and healthy individuals 





Patient No. Endotoxin 
(ng/ml) 
Patient No. Endotoxin 
(ng/ml) 
C1 1.81 C33 3.9 H2 5.06 
C2 3.63 C34 3.48 H3 4.9 
C3 3.1 C36 1.58 H4 4.65 
C4 3.19 C38 3.11 H6 4.51 
C5 3.08 C41 1.6 H7 4.65 
C6 5.87 C42 2.89 H9 3.32 
C7 4.01 C45 5.17 H11 4.4 
C8 3.65 C46 8.2 H12 4.51 
C9 5.15 C47 3.34 H13 4.69 
C10 4.15 C48 3.92 H14 4.28 
C11 3.8 C50 3.45 H16 3.18 
C12 4.87 C51 3.76 H18 3 
C13 5.21 C53 3.6 H19 2.89 
C14 4.77 C54 3.55 H20 1.76 
C15 3.88 C56 3.49 H22 1.92 
C16 3.53 C60 5.75 H23 2 
C17 4.82 C61 5.24 Mean *3.37 
C18 3.54 C62 4.64 SD 1.11 
C19 1.89 C63 5.77   
C20 2.09 C65 8.16   
C21 2.24 C69 1.89   
C22 2.9 C70 1.35   
C23 2.7 C71 4.48   
C24 3.46 C75 4.01   
C25 3.3 C78 1.7   
C26 2.8 C80 1.77   
C28 4.36 C86 1.66   
C29 4.7 C87 1.71   
C30 2.87 C90 3.12   
C31 3.9 C98 3.18   
  Mean *3.65   




   
 
 
Figure 3.3: Presence of endotoxin in the oral rinse samples of cancer patients on 
treatment and healthy individuals 
 
3.10 Endotoxin in the oral rinse samples of cancer patients with and without oral 
mucositis 
The results of the endotoxin concentration in the oral rinse samples of cancer patients with 
and without oral mucositis are shown in Table 3.10 and Figure 3.4. In cancer patients with 
oral mucositis, the range of endotoxins was 1.35ng/ml to 8.2ng/ml, with a mean value of 
4.1ng/ml. In cancer patients without oral mucositis, the range of endotoxins was 1.6ng/ml to 
5.87ng/ml with a mean value of 3.53ng/ml. The difference in the quantities of endotoxins 


































   
Table 3.10: Presence of endotoxin in the oral rinse samples of cancer patients with and 
without oral mucositis 
Cancer patients with oral mucositis (n=12) Cancer patients with no oral mucositis (n=48) 
Category Patient No. Endotoxin 
(ng/ml) 
Category Patient No. Endotoxin 
(ng/ml) 
Grade I C34 3.48 None C1 1.81 
 C42 2.89  C2 3.63 
 C46 8.2  C3 3.1 
 C62 4.64  C4 3.19 
 C69 1.89  C5 3.08 
 C70 1.35  C6 5.87 
 C71 4.48  C7 4.01 
 C75 4.01  C8 3.65 
Grade II C36 1.58  C9 5.15 
 C65 8.16  C10 4.15 
Grade III C25 3.3  C11 3.8 
Grade IV C45 5.17  C12 4.87 
 Mean *4.1  C13 5.21 
 SD 2.26  C14 4.77 
    C15 3.88 
    C16 3.53 
    C17 4.82 
    C18 3.54 
    C19 1.89 
    C20 2.09 
    C21 2.24 
    C22 2.9 
    C23 2.7 
    C24 3.46 
    C26 2.8 
    C28 4.36 
    C29 4.7 
    C30 2.87 
    C31 3.9 
    C33 3.9 
    C38 3.11 
    C41 1.6 
    C47 3.34 
    C48 3.92 
    C50 3.45 
    C51 3.76 
    C53 3.6 
    C54 3.55 
    C56 3.49 
    C60 5.75 
    C61 5.24 
    C63 5.77 
    C78 1.7 
    C80 1.77 
    C86 1.66 
    C87 1.71 
    C90 3.12 
    C98 3.18 
    Mean *3.53 
    SD 1.14 
*P=0.6501 
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Figure 3.4: Presence of endotoxin in the oral rinse samples of cancer patients with and 
without oral mucositis 
 
3.11 Endotoxin in the oral rinse samples of cancer patients with and without aerobic 
gram negative bacteria  
The results of the endotoxin concentration in the oral rinse samples of cancer patients with 
and without aerobic gram negative bacteria are shown in Table 3.11 and Figure 3.5. In cancer 
patients with aerobic gram negative bacteria, the range of endotoxins was 1.7ng/ml to 
5.77ng/ml with a mean value of 3.39ng/ml. In cancer patients without aerobic gram negative 
bacteria, the range of endotoxins was 1.58ng/ml to 8.16ng/ml with a mean value of 3.8ng/ml. 































   
Table 3.11: Presence of endotoxin in the oral rinse samples of cancer patients with and 
without aerobic gram negative bacteria  





Category Patient No. Endotoxin 
(ng/ml) 
With AGNB C1 1.81 Without AGNB C2 3.63 
(n=23) C10 4.15 (n=37) C3 3.1 
 C16 3.53  C4 3.19 
 C18 3.54  C5 3.08 
 C30 2.87  C6 5.87 
 C31 3.9  C7 4.01 
 C34 3.48  C8 3.65 
 C38 3.11  C9 5.15 
 C48 3.92  C11 3.8 
 C50 3.45  C12 4.87 
 C51 3.76  C13 5.21 
 C54 3.55  C14 4.77 
 C56 3.49  C15 3.88 
 C60 5.75  C17 4.82 
 C62 4.64  C19 1.89 
 C63 5.77  C20 2.09 
 C70 1.35  C21 2.24 
 C71 4.48  C22 2.9 
 C78 1.7  C23 2.7 
 C86 1.66  C24 3.46 
 C87 1.71  C25 3.3 
 C90 3.12  C26 2.8 
 C98 3.18  C28 4.36 
 Mean *3.39  C29 4.7 
 SD 1.19  C33 3.9 
    C36 1.58 
    C41 1.6 
    C42 2.89 
    C45 5.17 
    C46 8.2 
    C47 3.34 
    C53 3.6 
    C61 5.24 
    C65 8.16 
    C69 1.89 
    C75 4.01 
    C80 1.77 
    Mean *3.8 




   
 
Figure 3.5: Presence of endotoxin in the oral rinse samples of cancer patients with and 




The flow diagram of the study and the results are summarised in Figure 4.1. These 
results are discussed in this section. 
Cancer patients develop oral mucositis due to the immunosuppression, cancer therapy and the 
therapy-related changes in the oral cavity. It causes pain, an altered taste sensation, painful 
swallowing, subsequent dehydration with malnutrition and hence affects the patient’s quality 
of life. It also causes imbalance between commensal and opportunistic bacteria (Sixou et al, 
1998). Some of these opportunistic bacteria such as aerobic gram negative bacteria, Candida 
species, Streptococci and Staphylococci become established in the lesions of oral mucositis 
and may contribute in the pathogenesis. Blood stream infections are common in patients with 
higher grades oral mucositis (Panghal et al, 2012). These aerobic gram negative bacteria are 
known to produce endotoxins as virulence factors. Although the involvement of endotoxins 
in the development of other systemic bacterial infections is well described, the role of 
endotoxins in oral mucositis is not known. Therefore, this study investigated the presence of 
aerobic gram negative bacteria and endotoxins in the oral cavities of patients receiving cancer 
treatment and their role in the development of oral mucositis. In addition, the presence of 
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4.1 Streptococci and S. aureus 
Streptococci and S. aureus 
Oral Streptococci are the principle oral commensal bacteria of the oral cavity which usually 
occur in the form of biofilm. They are found in health and disease; however, increased 
numbers represent poor health and poor oral hygiene. In addition, high counts of Streptococci 
particularly S. mutans suggests caries activity in the oral cavity. The results in this study 
showed that healthy individuals (98%) as well as cancer patients (100%) carried Streptococci.  
 
Complications of chemotherapy can illicit temporary impairment of the salivary gland 
function, changes in the quantity and quality of saliva and suppress the oral host’s defence 
against microorganisms, thus allowing oral infections to develop. Consequently, this favours 
dental bacterial plaque accumulation, gingival inflammation and the abundance of cariogenic 
bacteria such as S. mutans and lactobacilli in these patients (Pendersen, 2016). This was 
similarly seen in the Streptococcal counts in cancer patients in this study, as they were 
significantly high compared to healthy individuals.  
  
 
Literature on the number of Streptococci and Staphylococci during cancer treatment is 
controversial. Bergmann (1991) and Wahlin & Holm (1988) showed that during cancer 
treatment there was no increase in Streptococci and S. aureus, which may be explained by the 
concomitant use of antibiotics, antifungals and the use of chlorhexidine rinses during 
chemotherapy, as well as the cytotoxic effects of chemotherapy itself (O’ Sullivan et al 
1993). However, other studies have reported increases in Streptococci and S. aureus (Sixou et 
al, 1998, Main et al, 1984, Almståhl et al, 2008). The increase in these bacteria occurs as a 
result of hyposalivation and xerostomia and it can increase the risk of development of dental 
caries (Hu et al, 2013, Su et al, 2011, Keene and Fleming, 1987). Similarly, the cancer 
patients in this study were not on any topical or systemic antimicrobials and 88% of patients 
complained of a dry mouth with 58% of patients presenting with caries, thus contributing to 
the high counts of Streptococci in cancer patients.  In addition, intergeneric co-aggregation 
and other symbiotic relationships also play a role in the occurrence of these bacteria in the 
oral cavity (Peterson et al, 1990). 
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Staphylococci are not considered to be part of the normal oral flora, although they have been 
found colonized in high numbers in healthy individuals. In this study, the oral carriage of S. 
aureus was 52% in cancer patients and 36% in healthy individuals. This colonization seems 
to coincide with the presence of other microorganism such as Candida albicans and 
Streptococcus pyogenes (Smith et al, 2001). This was similarly seen in this study, where the 
oral carriage of S. aureus (52%) and Candida albicans (54%) was not different. 
 
S. aureus, in its pathogenic state has been found in oral mucositis associated with 
haematological malignancies and cancer treatment. Some strains of S. aureus produce and 
secrete enzymes and toxins, thereby enhancing its pathogenicity and exacerbating oral 
mucosal damage (Smith et al, 2001). As S. aureus may be part of a complex group of 
microorganisms, other microorganisms such as Escherichia coli strains can be found present 
in these ulcerated lesions, which can act symbiotically with S. aureus and further aggravate 
oral mucositis (Bagg et al, 1995). In this study, cancer patients with oral mucositis, although 
colonized with Staphylococci, presented with a higher prevalence for Candida species 
compared to aerobic gram negative bacteria, which may be related to the cancer treatment 
and xerostomia. As cancer patients on intensive cytotoxic anticancer treatment are associated 
with xerostomia and at any stage can present with neutropenia, the prevalence of 
Staphylococci and Streptococci is associated with great morbidity in oral mucositis. In the 
present study, the prevalence of S. aureus was not significantly different in patients with oral 
mucositis and patients without oral mucositis. 
 
In patients undergoing myelosuppresive chemotherapy, oral Streptococci and Staphylococcus 
spp. are routinely found to cause bacteraemia originating from the oral cavity. In ulcerative 
oral mucositis, bacteraemia originating from oral viridans Streptococci in the oral cavity such 
as Streptococcus mitis and Streptococcus oralis, have been found (Raber-Durlacher et al, 
2013). Therefore, although the role of oral Streptococci in oral mucositis is not clear, the risk 
of systemic infections, bacteraemia and septicaemia cannot be excluded (Elting et al, 1992, 




   
4.2 Candida species 
Various species of Candida including C. albicans are known to cause oral candidiasis and 
they have been found in high numbers in the cancer treatment-related oral ulcers and angular 
chelitis (Wahlin & Holm, 1988).  
 
In this study, C. albicans carriage was found to be 54% amongst patients undergoing radio- 
and chemotherapy. Patients treated with chemotherapy were noted to have an overall greater 
prevalence of C. albicans colonization, which may be due to the systemic nature of cytotoxic 
chemotherapy treatment and xerostomia related to the drugs and radiation (Redding et al, 
1999, Al-Abeid et al, 2004, Ramirez-Amador et al, 1997). There is no definite colony count 
that has been established that allows for the difference between commensalism and disease. 
However, higher counts may predict the possibility of the development of infection. In this 
study it was shown that the prevalence of Candida carriage was high in patients undergoing 
cancer treatment compared to healthy individuals and cancer patients with oral mucositis 
compared to the cancer patients without oral mucositis. Therefore, the role of Candida in the 
development of infection and exacerbation of oral mucositis cannot be excluded. Similar 
results were reported by Gaetti-Jardim et al in 2011 where Candida was frequently noted in 
patients with grade III and IV oral mucositis. Other reasons that may have contributed to the 
Candida colonization would be from poor oral health care and the patient’s nutritional status 
during cancer treatment, partly due to low socio-economic factors and poor education as seen 
in less developed countries (Panghal et al, 2012). 
 
Malignancies and related chemotherapy and radiation are known to compromise the cell 
mediated host immunity which generally controls fungal infections. Both types of cancer 
therapies are able to cause oral mucositis resulting from hyposalivation and xerostomia which 
increases oral yeast proliferation, colonization and infection (Schelenz et al, 2011, 
Samaranayake et al, 1984). Therefore, to prevent infection it is important to maintain low 
counts of Candida in the oral cavity during cancer treatment. 
 
The predominant species isolated was C. albicans. Nevertheless, the results showed that 
Candida species other than C. albicans colonized the oral cavities of cancer patients. The 
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presence of non-albicans species may be due to immunosuppression and their reduced ability 
to prevent colonization. Similar results have been reported by Gaetti-Jardim et al, 2011, 
Laheij et al, 2012, Panghal et al, 2012 and Ramla et al, 2016. The second most frequently 
isolated species was C. glabrata which is known to be found in patients undergoing cancer 
therapy and consistent with other reports (Schelenz et al, 2011, Al-Abeid et al, 2004, Safdar 
et al, 2001, Ramla et al, 2016). These results are important because many non-albicans 
Candida species are known to be resistant to many commonly used antifungal drugs (Pfaller 
and Diekema, 2012). In addition, these yeasts other than C. albicans are reported to cause 
candidemia in patients with malignancies as a result of probably the haploid nature and the 
ability to mutate rapidly (Hachem et al, 2008). Occurrence of more than one species of 
Candida was also noted only in the oral cavities of cancer patients which is similar to 
previous reports (Ramla et al, 2016, Davies et al, 2006). Management of infections in these 
patients can be challenging because many of these species other than C. albicans are often 
resistant to commonly used drugs (Schelenz et al, 2011). For example, 10-25% of C. 
tropicalis, 35% of C. glabrata and 75% of C. krusei are found to be resistant to fluconazole 
(Krcmery and Barnes, 2002). 
Therefore, during cancer treatment, it is important to perform microbiological analysis of oral 
cavity samples. 
 
4.3 Aerobic gram negative bacteria 
The human oral cavity harbours approximately 700 different types of bacteria as 
commensals. However, aerobic gram negative bacteria (AGNB) particularly from the group 
of Enterobacteriacae do not form part of this flora. Nevertheless, it is generally known that 
during severe underlying disease, these bacteria are carried transiently into the oropharynx. 
Due to unknown reasons, these bacteria are also carried by generally healthy people, as also 
shown in this study. Denudement of the oral mucosa from the fibronectin exposes receptor 
sites required for the attachment of AGNB which is responsible for the colonization of these 
bacteria (Dal Nogare et al, 1987).  
 
In literature, the prevalence rate of the carriage of AGNB is unclear. In this present study, the 
carriage rate of AGNB in cancer patients was 24% and in the healthy individuals it was 14%, 
which was not significantly different from one another. O’Sullivan et al, (1993) also found 
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that during chemotherapy, 29% of children with acute leukemia carried AGNB in their oral 
cavity. In contrast, Wahlin & Holm (1988) reported that 70% of cancer patients carried 
AGNB including K. oxytoca, E. coli, P. aeruginosa, Serratia species, E. cloacae, P. vulgaris 
and E. sakazaki in their oral cavity at some point during treatment. The same author reported 
a few years later that 86% of cancer patients carried AGNB in their oral cavity compared to 
12% of healthy individuals (Wahlm et al, 1991). Similarly, 62.2% prevalence in cancer 
patients and 28% in healthy individuals was reported and it was attributed to the decreased 
white blood cell counts and the presence of oral mucositis (Galili et al, 1992). In acute 
leukemic patients during treatment, AGNB were present but after treatment the numbers 
decreased and the role in the infectious process was not established (Fainstein et al, 1981). 
These controversial results suggest that there are other physiological and habitual factors that 
might be contributing towards the colonization of the oral cavity with AGNB in diseased as 
well as healthy people. Although none of our patients were tobacco chewers, tobacco 
chewing among patients with oral squamous cell carcinoma is known to frequently carry 
AGNB compared to the non-chewers (Sonalika et al, 2012). Alcoholics and diabetics are also 
reported to carry AGNB frequently (Mackowiak et al, 1979). 
 
Nevertheless, although in the present study, AGNB was not studied at time intervals during 
cancer treatment, studies have shown that often there is an imbalance of oral flora. The 
carriage and quantities of AGNB have been reported to increase during the treatment time 
period (Samaranayake et al, 1984 and Main et al, 1984). These results have been attributed to 
the decreased saliva flow and the reduction in salivary amylase and IgA (Main et al, 1984). 
 
Minah et al, (1986) noted within 14 days of treatment, there was a sharp increase in AGNB 
and due to these AGNB, there was a reduction in indigenous flora. Similar results were 
reported by Renard et al, (1986) who studied these bacteria up to 28 days of treatment. 
Within twelve weeks of chemotherapy, patients also showed an increase in occurrence of E. 
coli and Klebsiella spp. (Main et al, 1984).  
 
It is clear that cancer patients carry AGNB and the carriage can increase with the length of 
treatment time period. This does not necessarily mean that they contribute towards the 
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exacerbation of oral mucositis. In the present study, there was no difference in the prevalence 
of AGNB between the cancer patients with and without oral mucositis. In contrast Gaetti-
Jardim et al, (2011) found that AGNB were frequently present in patients with of grade III 
and IV oral mucositis. Similarly, Soares et al, (2011) found E. coli and K. pneumonia less 
frequently in children with leukemia on treatment and in the children with oral mucositis. Up 
to 58% of cancer patients particularly those with oral mucositis carried AGNB in their oral 
cavity and the predominant species was K. pneumonia (Panghal et al, 2012), which suggest 
that AGNB may play some role in the pathogenesis of oral mucositis. 
  
Oral mucositis develops from mucosal changes that occur from the thinning of oral tissues to 
ulceration (Redding, 2005). Even if AGNB may or may not cause any pathology, the mere 
presence of ulceration can allow these bacteria to enter into the deep tissues and into the 
blood stream. Therefore, the rate of blood stream infections due to AGNB in cancer patients 
has been found to be high (Gudiol et al, 2013 and Panghal et al, 2012). Blood stream 
infections are more common in patients with haematological malignancies compared to the 
patients with solid tumors. Patients with oral mucositis are known to carry their oral flora in 
their blood stream. For example 23% of leukemia patients carried AGNB in their oral cavity 
out of which 18% carried these bacteria were found in their bloodstream (Anirudhan et al, 
2008). This transmission was much higher with AGNB compared to the fungi and gram 
positive bacteria (Anirudhan et al, 2008). Similarly 57% of blood cultures were positive for 
AGNB in cancer patients with fever (Panghal et al, 2012).  
 
The results in this study suggests that in cancer patients compared to the healthy individuals, 
whether the carrier rate of AGNB is high or not, they are present and can increase with the 
treatment time period and there is the likelihood of systemic and bloodstream infections, due 
to the presence of these bacteria.  
 
 
AGNB produce endotoxins which are known to interact with the host’s cells which produce 
proinflammatory cytokines and cause pathology. Therefore, the presence of endotoxins in the 
oral cavities of cancer patients and healthy individual was also studied. 
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4.4 Endotoxin 
Endotoxins are lipopolysaccharide produced by aerobic gram negative and anaerobic bacilli. 
In the oral cavity mostly anaerobic gram negative bacilli exist and are implicated in 
periodontal diseases. Periodontal pathogens present are Porphyromonas gingivalis, 
Prevotella intermedia, Fusobacterium nucleatum, Treponema denticola and many more. 
These bacteria also produce endotoxins however, the endotoxicity is 1000 times lower than 
the endotoxins produced by E. coli which is an aerobic gastrointestinal bacillus and generally 
not found in the oral cavity. Endotoxin detection tests for the detection of anaerobic bacteria 
are not available but the E. coli endotoxin kit-based tests have been developed and these are 
commercially available. It is for this reason the chromogenic Limulus gelation assay test 
which uses the E. coli endotoxin, was used. 
 
In our study groups (60 cancer patients and 16 healthy individuals), the range of endotoxins 
detected was 1.35ng/ml to 8.2ng/ml. In the oral rinse samples of cancer patients and healthy 
individuals, a mean endotoxin concentration of 3.65ng/ml and 3.37ng/ml was found 
respectively. The difference in the endotoxin between the two groups was not significant 
(p=0.5). The Hycult Biotech Limulus Amebocyte Lysate (LAL) assay kit that was used in 
this study is based on a similar kit that was used by Leenstra et al, (1996). Our endotoxin 
levels were found to be lower than the endotoxins reported by Leenstra et al, (1996). In their 
study, they measured endotoxin levels in oral rinse samples of 15 healthy individuals which 
were found ranging between 3ng/ml and 30ng/ml with a mean oral endotoxin level of 
20ng/ml.  However, in their study group these healthy individuals did not carry AGNB, 
therefore the results were multiplied by 1000 to adjust for the potency of anaerobic oral 
bacteria. This means that our endotoxin levels were much higher than those reported by 
Leenstra et al, (1996).  
 
In Milln’s study, the endotoxin concentration range was between 5.8ng/ml and 36ng/ml with 
a mean concentration of 19.1ng/ml for the paediatric cancer patients, which was similar to 
Leenstra et al, (1996) findings in healthy individuals of 20ng/ml. The healthy paediatric 
population had a mean endotoxin range of 3.1ng/ml and 20.7ng/ml with a mean salivary 
endotoxin concentration of 12.75ng/ml. Millns et al, (1999) describes that the false positive 
results in the leukemic patients were possible due to either bacterial clearance with the release 
of endotoxins at the same time or due to the absence of routine neutralizing effects  from 
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platelets, proteins and leucocytes  on endotoxins especially in immunocompromised, 
neutropenic patients or due to antibiotic-induced release of endotoxins (Goto and Nakamura 
1980; Shenep et al, 1985 and Shenep and Mogan, 1984). Millns et al, (1999) findings showed 
that salivary endotoxins were a poor predictor of sepsis and they did not correlate with the 
ANGB carriage in the oropharynx, but rather that a relationship existed between neutropenia 
and the raised salivary endotoxins. Similarly in the present study no correlation existed 
between the carriage of AGNB and endotoxin levels. 
  
In the present study, the range of endotoxins in cancer patients with oral mucositis was 
1.35ng/ml to 8.2ng/ml with a mean value of 4.1ng/ml, where as in cancer patients without 
oral mucositis, the range of endotoxins was 1.6ng/ml to 5.87ng/ml with a mean value of 
3.53ng/ml. Although the endotoxin levels were slightly higher in patients with oral mucositis, 
it was not significantly higher compared to the levels in patients without oral mucositis. Only 
12 out of 100 cancer patients had oral mucositis. The sample size was too small for any 
inferences to be made. Nevertheless, given the limitations, endotoxins may not have 
contributed towards the pathogenesis of oral mucositis. This result could only be compared to 
the studies done by Leenstra et al, (1996) and Millns et al, (1999), as there are no other 
studies available on PUBMED. 
 
These endotoxin levels, although not very high, raised the question of the origin of endotoxin. 
Gram negative anaerobic oral bacteria also produce endotoxins but they are slightly different 
in the composition and potency. The endotoxin from anaerobic bacterium lack two essential 
structures i.e. 2-keto-3 deoxyoctonate and heptose (Johne and Bryn, 1986) and therefore 
requires a concentration of a 1000 times higher to cause lethality in chick embryos and mice 
(Kasper, 1976, John and Bryn, 1986).  Endotoxins from oral bacteria such as Porphyromonas 
gingivalis (previously called Bacteroides gingivalis), Prevotella melaninogenicus (previously 
called Bacteroides melaninogenicus), Fusobacterium and Veillonella have been characterised 
and tested against chick embryos, rabbits and mice (Sveen et al, 1977, Koga et al, 1985, 
Hofstad and Sveen, 1979 and Grehn, 1980). The results showed that much higher 
concentrations of endotoxins were required to cause lethality. This justifies the 
commensalism of these anaerobic bacteria. In the present study, the detected endotoxins may 
have been produced by aerobic or anaerobic oral bacteria and in those who were carriers of 
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AGNB, it may have been produced by these oral bacteria as well as AGNB. Therefore an 
attempt was made to compare the endotoxin levels in cancer patients with and without 
AGNB. 
 
In cancer patients with aerobic gram negative bacteria, the range of endotoxins was 1.7ng/ml 
to 5.77ng/ml with a mean value of 3.39ng/ml. In the cancer patients without aerobic gram 
negative bacteria, the range of endotoxins was 1.58ng/ml to 8.16ng/ml with a mean value of 
3.8ng/ml. The difference in the quantities of endotoxins between the two groups was not 
significant (p=0.45). These results suggest that these endotoxins were not produced by the 
AGNB and that the oral anaerobic bacteria may have been responsible for them. Considering 
this, the patient’s general oral hygiene is important. During cancer treatment, the increase in 
periodontal pathogens has been reported and their role in the oral mucositis has been 
suggested (Sixou et al, 1998 and Laheij et al, 2012).  
 
The normal amount of endotoxins levels circulating in a healthy individual is 0.3-10.4 pg/ml 
(O'Brien and Bruce, 2007).  There are recommendations for the allowable endotoxin limit for 
biological products, drugs and devices. According to the Food and Drug Administration 
(FDA), water for Injection, sterile water for Injection and sterile water for irrigation have an 
allowable endotoxin limit of 0.025ng/ml. The maximum allowable endotoxin exposure for 
humans is calculated as 0.5 ng/Kg/Hour (or 350 EU or 35ng/ml per adult for 70Kg person per 
hour) to avoid fever and hypotension from endotoxin contamination (FDA, 2012). Our oral 
endotoxin readings were much lower than these allowable limits and the potency of this 
endotoxin would be much lower because the majority produced were by the anaerobic 
bacteria.  
 
In addition, in the oropharyngeal and gastrointestinal tract area there are potent defense 
mechanisms which generally controls the absorption and clearance of toxins. The first line of 
defense, which is the intactness of tissues, may have failed in the case of oral mucositis. 
However, once absorbed, macrophages of the oropharynx and lymphatic tissue neutralises 
endotoxin. In addition, platelets, proteins and leucocytes present in the blood also further 
neutralise endotoxins. Not forgetting, there is the physical clearance and removal of 
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endotoxins and AGNB via physical mechanisms of reflex, tongue movements and the 
salivary flow. Salivary mucins are also known to neutralise endotoxin from the oral cavity 
(Daly et al, 1980). Nevertheless, high counts of AGNB in the oral cavity may increase the 
quantities of endotoxin and the sub-functioning oropharynx-associated lymphatic tissues in 
the immunosuppressed patient may not cope with the natural clearance. In some of our 
patients, AGNB was detected only after an enrichment technique meaning that the counts of 
AGNB in the actual oral rinse were very low. 
 
4.5 Prevention, treatment and recommendations 
 
While a number of the adverse effects associated with cancer treatment are well managed, 
oral mucositis remains an area for debate in the efficient management of this condition (De 
Sanctisa et al, 2016). Although several approaches have been recommended for the treatment 
of oral mucositis, no specific prophylactic agent or intervention has been devised for the 
effective prevention and management of this condition (Köstler et al, 2001), also considering 
that these patients already are taking multiple cancer drugs. 
 
A systematic literature review was done in relation to the prophylaxis and management of 
oral mucositis over the past 20 years and this was assessed by clinical experts and a 
consensus by 40 different multidisciplinary experts such oncologists, infectious disease 
physicians, nurses, nutritionists and oral health professionals. Their aim was to reach 
consensus to the prophylaxis and management of the condition (De Sanctisa et al, 2016). 
Although oral mucositis can develop as a complication of the cytotoxic therapy, patient risk 
factors have been highlighted to influence the progression of oral mucositis, such as poor oral 
hygiene, periodontal disease, alcohol, tobacco use and immunosuppression related to the 
treatment or from other diseases such as diabetes mellitus (Meurman et al., 1997). 
 
In this multidisciplinary approach, oral health professionals are recommended for the 
maintenance of good oral hygiene, periodontal disease and dental disease during pre-
treatment, during treatment and post treatment of cancer (Lalla et al, 2008). The practice of 
strict oral hygiene regimens, have been associated with lowering the incidence of oral 
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mucositis with the reduction in the colonization of opportunistic bacteria (Yoneda et al, 
2007).  
 
Numerous topical agents like barrier-protective agents which have been suggested to cover 
the ulcerated region to reduce symptoms, have been recommended for the prevention and 
treatment of oral mucositis, although these have been proven ineffective (De Sanctisa et al, 
2016). Topical antibacterial mouthwashes such chlorhexidine gluconate have been proposed. 
Many studies have been done to emphasize the positive effects of chlorhexidine to 
significantly reduce the incidence and treat this pathology (Ferretti et al, 1990, McGaw and 
Belch, 1985), but other randomised trials have proven them to be ineffective (Spijkervet et al, 
1989c and Weisdorf et al, 1989). In the study by Ferretti et al, (1990), evidence of the 
reduction of streptococci and yeasts were noted, although in the study by Spijkervet et al, 
(1989c), colonization of Candida spp, Streptococci spp, Staphylococci and aerobic gram 
negative bacteria were not reduced after five weeks of using chlorhexidine rinses compared 
to a placebo rinse. Evidence of the presence of gram negative bacteria persisting despite the 
use this oral rinse (Raybould et al, 1994) was found due to the low susceptibility of gram 
negative bacilli to chlorhexidine, the discomfort and possible aggravation of the condition 
associated with the mouthwash (Wahlin, 1989). It has also been found that the inefficacy of 
certain antifungals such as nystatin in combination with chlorhexidine against C. albicans in 
vitro, have been reported (Barkvoll and Attramadal, 1989). These and other antibacterial 
agents have been recommended but none impacting on a better quality of life. 
 
By selectively eliminating certain oral flora with antibiotic and antifungal lozenges 
(containing polymixin, tobramycin and Amphotericin B; or bacitracin, clotrimoxazole and 
gentamicin) in the hope that fewer patients would need a feeding tube and combat 
malnutrition, this did not reduce the severity of oral mucositis (Stokman et al, 2003 and 
Wijers et al. 2001). Polymyxin is used for the selective treatment for gram negative bacteria 
and Tobramycin has a role in treating bacterial infections, particularly gram negative 
infections. Amphotericin B is an antifungal used to treat systemic fungal infection (Saunders 
et al, 2013). Clotrimazole and fluconazole have been shown to reduce the candida 
colonization in patients with oropharyngeal candidiasis (Saunders et al, 2013), although 
fluconazole did not reduce the incidence of oral mucositis. This suggested that bacteria might 
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not be involved as the main aetiological factor in the pathogenesis of oral mucositis (Wijers 
et al, 2001). As candidiasis, such as the acute atrophic variant and oral mucositis can 
clinically present similar, fluconazole has not been recommended in the management of oral 
mucositis but rather for prophylaxis in patients with a high risk for mycotic infections and 
immunocompromised patients, such as diabetics (De Sanctisa et al, 2016).  The long term use 
of systemic antibiotics for oral mucositis prophylaxis in patients without neutropenia was not 
recommended as these bacteria may become resistant to the antibiotics (Saunders et al, 2013). 
 
In the present study, the antimicrobial sensitivity of AGNB shows that resistance to 
antibiotics was high in the Pseudomonas species found in cancer patients and Klebsiella 
species found in healthy individuals. Pseudomonas spp. are opportunistic human pathogens, 
where antibiotics such as fluoroquinolones, aminoglycosides, and imipenems are effective 
against these bacteria, however resistance towards these antibiotics have been developing 
rapidly (Yau et al, 2001). 
 
As oral mucositis develops due to multiple factors, several management approaches have 
been proposed, but no definite solution has finalized. Miscellaneous treatments such as 
cryotherapy, growth factors, pure natural honey and many more agents have been suggested 
but none have been effective either. De Sanctisa et al, (2016) highlights the importance of a 
multidisciplinary approach from health professionals of different disciplines and the need for 











   
CHAPTER 5 
CONCLUSIONS, LIMITATIONS AND FUTURE RESEARCH  
5.1 Conclusions 
The carriage of Candida species was found to be high in the oral cavities of cancer patients 
on radio and/or chemotherapy compared to the healthy individuals. However, carriage of 
Streptococci, S. aureus and aerobic gram negative bacteria was not different between the two 
groups. Cancer patients on radio and/or chemotherapy carried high number of Streptococci in 
their oral cavities compared to the healthy individuals. However, no difference in the counts 
of S. aureus and C. albicans was noted. The prevalence of Candida was high in the cancer 
patients with oral mucositis compared to the patients without oral mucositis. Cancer patients 
also carried a variety of Candida species including C. albicans and C. glabrata, and multiple 
species in their oral cavities compared to the healthy individuals. Cancer patients also carried 
a variety of aerobic gram negative bacteria compared to healthy individuals. Enterobacter 
cloacae and Klebsiella pneumonia were isolated from the oral cavities of both study groups. 
The antimicrobial sensitivity test results showed that aerobic gram negative bacteria were 
resistant to many antibiotics in cancer patients and healthy individuals. 
 
Endotoxin test results showed no significant difference in the endotoxins present in the oral 
rinses samples collected from cancer patients and healthy individuals, cancer patients with 
and without oral mucositis and cancer patients with and without aerobic gram negative 
bacteria. 
 
These results suggest that although cancer patients carry aerobic gram negative bacteria and 
endotoxins in their oral cavities, they may not contribute in the exacerbation of oral 
mucositis. However, Candida species may contribute in the exacerbation of oral mucositis 
and therefore, during cancer treatment, it is important to take preventative measures to 





   
5.2 Limitations 
 It would have been ideal to have a larger sample size. Due to the time and financial 
constraints only 100 cancer patients and 50 healthy individuals were included.  
 Thorough oral hygiene assessment was not possible as these cancer patients are often 
too ill to comply. It may have assisted in the interpretation of the microbiology 
results. 
 Endotoxin test was performed only on 76 oral rinse samples (60 cancer patients and 
16 healthy individuals) in duplicate. The cost of the endotoxin test was R 345.96 per 
sample and therefore more samples could not be tested. In addition, it is a kit based 
test. 
 Unfortunately only 12/100 cancer patients had oral mucositis. Ideally, it would have 
been better to have more patients with oral mucositis in order to have a reasonable 
comparison. 
 
5.3 Future research 
 A similar study can be undertaken with a larger sample size 
 Antifungal susceptibility tests can be performed on all the Candida isolates to 
determine a resistance pattern in our population 
 Anaerobic gram negative bacteria which are generally dental plaque-associated 
periodontal pathogens can be isolated and identified from this study population 
 Endotoxin testing can be performed more than twice per sample to eliminate any 
errors. 
 Aerobic gram negative bacteria from faecal samples and oral rinse can be compared 
in cancer patients to establish the origin of these bacteria as they do not form part of 
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CHAPTER 7 
APPENDICES 
Appendix A: Data collection sheets 
Data Collection sheet – Cancer patients 
Laboratory no.  Age:  Male:   Female: 
Type of Cancer: ____________________________ 
Type of Treatment: Chemotherapy and Radiation/ Chemotherapy 
Length of treatment: ____________________________________________ 
Present Stage of treatment (weeks): ________________________________ 
Name of Chemotherapy Drugs: ____________________________________ 
Nausea and vomiting:  Yes     No 
HIV status:  positive Negative  unknown 
Diabetes: Yes   No 
Other medical conditions: ________________________________________ 
Smoker:  Yes   No 
Dentures:  Yes   No 
Antimicrobials: Yes   No  
Other medication:  Yes   No  
Oral exam: Oral Mucositis: Yes   No 
Bleeding ulcers: Yes   No 
Degree of Pain: Mild   Moderate  Severe 
Loss of appetite: Yes   No 
Difficulty to swallow: Yes   No 
Altered taste:  Yes   No 
Grade of Oral Mucositis: 0 1 2 3 4 
Oral Hygiene: Halitosis  Yes   No 
  Plaque:  Yes   No 
  Swollen gums: Yes   No 
  Periodontitis:  Yes   No 
  Dry mouth:  Yes   No 
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  Dental caries:  Yes   No   
Consent form signed:   Yes   No 
Oral rinse collected:   Yes   No 
 
Data Collection sheet – Healthy individuals 
 
Laboratory no.    Age:  Male:    Female: 
Diabetes: Yes   No 
Other systemic illnesses: ________________________________________ 
 
Smoker:  Yes   No 
Dentures:  Yes   No 
Antimicrobials: Yes   No  
Other medication:  Yes   No  
 
Oral Hygiene: Halitosis  Yes   No 
  Plaque:  Yes   No 
  Swollen gums: Yes   No 
  Periodontitis:  Yes   No 
  Dry mouth:  Yes   No 
  Dental caries:  Yes   No   
 
Consent form signed:   Yes   No 







   
Appendix B: Consent form 
University of the Witwatersrand, Faculty of Health Sciences, Johannesburg 
Consent form  
Good Day, 
 
How are you? I am Dr Juliana Mathews from the Oral Microbiology at the Wits Dental 
School. My colleagues and I are doing a study on germs that are found in our mouth. These 
germs cause painful sores in our mouth especially in cancer patients who are under treatment. 
These germs are bacteria and fungi and sometimes patients have to take tablets and 
mouthwashes to cure it. Sometimes these medicines do not help to cure the sores in our 
mouth. We would like to study these germs and the study will show us how powerful they are 
in causing sores and whether the treatment will work or not. 
 
In order to do this study, I will check your mouth to see if you have these sores and how 
severe these sores are. We would like to collect a sample of oral rinse from your mouth. This 
will not cause any pain or discomfort. All you have to do is take this clean sterile water, put it 
in your mouth, rinse and collect it back into the jar given to you. It will not cause any harm.  
The sample will be processed at a laboratory. I may need to look at your medical records to 
see what cancer treatment you are on and how long you have been receiving it.  
 
You may or may not participate and it is entirely up to you.  What you decide will not affect 
your treatment.  If you agree to participate, you may withdraw from the study at any time 
without affecting your treatment. The sample will be collected once only during your normal 
visit.  If we find germs that cause sores in your mouth, your doctor will be notified. He will 
advise you on how to look after your mouth so that you don’t get sores. We will also know if 
you have developed resistance to the medicines used to treat the sores in South Africa or not 
and everybody will benefit from the knowledge. 
 
Your sample will be given a number and will be processed under a number. Your name will 
not appear anywhere on the results or on any publications. This study has been approved by 
the University Ethics Committee. Should you have any problems or queries with regards to 
ethics of this study, please contact Prof. P. Cleaton-Jones at 011 717 2301.  
 
If you are 18 years old or older, not diabetic (sugar-disease), do not smoke, do not wear any 
false teeth, are not taking antibiotics and are already on cancer treatment for at least two 
weeks, you may take part in the study.  
 
Patient’s name:      Investigator’s name: 
Signature:         Signature: 
 
Contact: Dr Juliana Mathews: cell no 083 799 2665, Prof M. Patel 011 717 2110 
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Appendix C: Ethics clearance certificate 
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Appendix D: Composition and preparation of Media  
Mitis Salivarius Agar 
90g  Mitis Salivarius Agar 
1000ml   Sterile distilled water 
0.25ml  Potassium tellurite solution 
Weigh 90g of Mitis Salivarius Agar. Suspend in 1000ml of sterilised distilled water. Boil 
to dissolve. Dispense medium into 250ml Boston bottles. Sterilize at 15 lb, 121 ºC for 15 
minutes in an autoclave. Cool the media to 50-55 ºC. Add 0.25ml Potassium tellurite 
solution, mix and pour plates. 
Chromagar Plates 
47.7 g  Chromagar™Agar 
1000 ml  Sterile distilled water 
Weigh 47.7g of Chromagar™ Agar. Dissolve this into one litre of sterile distilled water. 
Boil the media, with the temperature not being greater than 100ºC. Cool the media until it 
reaches about 45ºC-50ºC and pour plates.  
Sabouraud Agar 
65g Sabouraud agar 
1000 ml Distilled water 
Suspend Sabouraud agar in half the distilled water. Heat half the water to boiling point. 
Mix the two and heat to boiling point. Pour into large bottles and sterilize at 15lb, 121
o
C 
for 15 minutes in an autoclave. Cool at 45
o
C and pour plates. 
Phosphate Buffered Saline (PBS) 
4.2 g  Sodium chloride 
0.078 g Sodium dihydrogen phosphate 
0.64 g Sodium hydrogen phosphate 
500 ml Distilled water 
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Suspend the solids and then autoclave at 15 lb, 121
o
C for 15 minutes and dispense. 
MacConkey Agar 
50.0 g medium 
1000ml distilled water 
Heat half the water to boiling point  
Dissolve the powder in rest of the water and add to the boiling water. Pour into larger 
bottles to sterilize at 15 1bs for 15 min in autoclave, cool at 45
o
C and pour plates. 
Mueller Hinton Agar 
2.0 g Beef extract 
17.5 g Acid hydrolysate of casein 
1.5 g Starch 
17 g Agar 
1000 ml Distilled water 
Dissolve solids into distilled water, boil, adjust pH to 7.3, autoclave at 121
o
C, 15 lb for 15 
minutes. Cool to 45
o
C and pour plates. 
Baird Parker Agar 
12.0g   Glycine 
10.0g   Pancreatic Digest of Casein 
10.0g   Sodium Pyruvate 
5.0g   Beef Extract 
5.0g   Lithium Chloride 
1.0g   Yeast Extract 
60.0ml   Egg Yolk Tellurite Enrichment 
20.0g   Agar 
Final pH 7.0 +/- 0.2 at 25ºC. 
* Adjusted and/or supplemented as required to meet performance criteria. 
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Suspend desired quantity (as per manufacturer’s instruction) of the medium in 940 ml 
deionized water. Boil to dissolve the medium and sterilise by autoclaving at 121°C for 15 
minutes. Cool to 50°C and aseptically add 60ml of Egg Yolk Tellurite Emulsion. Mix 
well before pouring into sterile Petri Dishes. 
 
Appendix E: Raw data of microbiological results 
Laboratory Results- Cancer Patients 
  











20C  AGNB API 20E  
Endotoxin 
ng/ml 
C1 512000 0 85 Candida famata  
Enterobacter 
cloacae  1.81 
C2 1444000 12400 0 N/A N/A 3.63 
C3 1417000 0 20 Candida famata  N/A 3.1 
C4 207000 10 0 N/A N/A 3.19 
C5 5080000 40 0 N/A N/A 3.08 
C6 452000 0 10 Candida famata  N/A 5.87 
C7 960000 0 0 N/A N/A 4.01 
C8 2320000 10 0 N/A N/A 3.65 
C9 144000 0 0 N/A N/A 5.15 
C10 5520000 0 210 Candida glabrata  
Klebsiella 
pneumoniae  4.15 
C11 208000 0 0 N/A N/A 3.8 
C12 950000 10 50 Candida famata  N/A 4.87 
C13 300000 0 20 Candida famata  N/A 5.21 
C14 87000 10 0 N/A N/A 4.77 
C15 370000 30 0 N/A N/A 3.88 
C16 5500000 0 20 Unidentifiable 
Enterobacter 
cloacae  3.53 
C17 2680000 0 0 N/A N/A 4.82 
C18 3840000 50 0 N/A 
Klebsiella 
pneumoniae  3.54 
C19 470000 90 0 N/A N/A 1.89 
C20 2080000 1200 0 N/A N/A 2.09 
C21 1800000 165 0 N/A N/A 2.24 
C22 1040000 0 80 Unidentifiable N/A 2.9 
C23 3600000 0 0 N/A N/A 2.7 
C24 502000 10 280 Candida albicans  N/A 3.46 
C25 633000 18 30 Candida albicans  N/A 3.3 
C26 4350000 0 10 Candida albicans  N/A 2.8 
C27 840000 15000 290 Unidentifiable N/A N/A 
C28 1820000 0 30 Candida albicans  N/A 4.36 
C29 1220000 0 20 Candida albicans  N/A 4.7 
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C31 812000 400 30 Candida albicans Escherichia coli  3.9 
C32 554000 0 30 Candida albicans  N/A N/A 
C33 490000 10 0 N/A N/A 3.9 
C34 650000 0 0 N/A Kluyvera spp.  3.48 
C35 500000 0 0 N/A N/A N/A 
C36 7340000 20 260 Candida albicans  N/A 1.58 
C37 2300000 10 0 N/A N/A N/A 
C38 2180000 2140 180 
Candida albicans, 
Candida glabrata  Escherichia coli   3.11 
C39 432000 50 2300 Candida albicans  N/A N/A 
C40 2600000 0 1400 Candida albicans  N/A N/A 
C41 1060000 0 0 N/A N/A 1.6 
C42 2880000 20 210 Candida albicans  N/A 2.89 
C43 120000 0 20 Candida albicans  N/A N/A 
C44 5480000 0 0 N/A N/A N/A 
C45 2140000 40 1040 Candida albicans N/A 5.17 
C46 720000 0 10  Candida albicans N/A 8.2 
C47 6032000 80 560 Candida albicans N/A 3.34 
C48 1700000 30 260 Candida glabrata  
Enterobacter 
cloacae 3.92 
C49 2280000 0 0 N/A N/A N/A 




cloacae  3.45 
C51 1340000 30 230 Candida glabrata  Escherichia coli  3.76 
C52 3960000 90 10 
Saccharomyces 
cerevisiae  N/A N/A 
C53 770000 0 0 N/A N/A 3.6 
C54 460000 20 0 N/A 
Aeromonas 
hydrophila  3.55 
C55 1088888 15000 40 Candida albicans N/A N/A 
C56 2320000 90 0 N/A 
Enterobacter 
cloacae  3.49 
C57 400000 0 40 Candida albicans  N/A N/A 
C58 3480000 15000 50 Candida albicans N/A N/A 
C59 1440000 110 0 N/A N/A N/A 
C60 1080000 130 90 
Candida albicans, 
Saccharomyces 
cerevisiae Pantoea  5.75 
C61 150000 20 0 N/A N/A 5.24 
C62 150000 280 0 N/A 
Pseudomonas 
aeruginosa  4.64 
C63 630000 10 0 N/A 
Pseudomonas 
aeruginosa  5.77 
C64 930000 0 0 N/A N/A N/A 
C65 1310000 0 40 Candida albicans N/A 8.16 
C66 140000 0 10 Candida albicans N/A N/A 
C67 1840000 70 0 N/A N/A N/A 
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C68 440000 0 0 N/A N/A N/A 
C69 9520000 730 0 N/A N/A 1.89 
C70 1420000 0 3840 Candida albicans Escherichia coli  1.35 




aeruginosa  4.48 
C72 16720000 190 0 N/A N/A N/A 
C73 24880000 130 1880 Candida albicans N/A N/A 
C74 1820000 0 0 N/A N/A N/A 
C75 960000 0 60 Candida albicans N/A 4.01 
C76 2640000 0 0 N/A N/A N/A 
C77 172000 0 20 Candida albicans N/A N/A 
C78 180000 430 400 
Candida albicans, 
Candida glabrata Pantoea  1.7 
C79 360000 0 20 Candida albicans N/A N/A 
C80 281000 0 0 N/A N/A 1.77 
C81 6360000 0 6770 
Candida albicans,  
Candida glabrata N/A N/A 
C82 2100000 10 0 N/A N/A N/A 
C83 515000 10 0 N/A N/A N/A 
C84 107000 0 30 Candida albicans N/A N/A 
C85 1280000 0 0 N/A N/A N/A 
C86 1030000 0 0 N/A Serratia rubidaea  1.66 
C87 2540000 30 30 Candida albicans 
Enterobacter 
cloacae  1.71 
C88 2440000 0 50 Candida albicans N/A N/A 
C89 860000 0 10 Candida albicans N/A N/A 
C90 720000 60 20 Candida albicans 
Pasteurella 
pneumotropica  3.12 
C91 1720000 0 1390 
Candida albicans, 
Candida glabrata N/A N/A 
C92 130000 0 130 Candida albicans N/A N/A 
C93 3920000 240 0 N/A Klebsiella oxytoca    
C94 1280000 30 70 Candida albicans N/A N/A 
C95 1280000 0 0 N/A N/A N/A 
C96 3540000 10 180 Candida albicans N/A N/A 
C97 4180000 0 20 
Saccharomyces 
cerevisiae N/A N/A 
C98 740000 10 610 Candida albicans Citrobacter koseri  3.18 
C99 854000 6240 0 N/A N/A N/A 







   
Lab Results- Healthy Individuals 
   











20E  Endotoxin 
H1 1551000 0 0 N/A N/A N/A 
H2 1040000 0 50 Candida albicans  N/A 5.06 
H3 1760000 0 0 N/A N/A 4.9 
H4 830000 0 0 N/A N/A 4.65 
H5 1440000 0 6000 Candida krusei  
Klebsiella 
pneumoniae N/A 
H6 11000 0 0 N/A N/A 4.51 
H7 700000 100 10  Candida famata  N/A 4.65 
H8 253000 0 0 N/A 
Enterobacter 
cloacae  N/A 
H9 696000 0 0 N/A N/A 3.32 
H10 1136000 0 0 N/A 
Klebsiella 
pneumoniae  N/A 
H11 3560000 0 0 N/A N/A 4.4 
H12 150000 0 0 N/A N/A 4.51 
H13 2280000 20 0 N/A N/A 4.69 
H14 196000 0 0 N/A N/A 4.28 
H15 292000 30 0 N/A 
Klebsiella 
oxytoca  N/A 
H16 180000 10 10 Candida albicans  N/A 3.18 
H17 24000 0 0 N/A N/A N/A 
H18 700000 10 5200  Candida albicans  N/A 3 
H19 3080000 110 0 N/A N/A 2.89 
H20 1500000 0 0 N/A N/A 1.76 
H21 1860000 10 0 N/A N/A N/A 
H22 0 0 0 N/A N/A 1.92 
H23 1200 0 40 Candida albicans  N/A 2 
H24 176000 0 0 N/A N/A N/A 
H25 2000000 0 0 N/A N/A N/A 
H26 270000 0 0 N/A N/A N/A 
H27 1320000 0 0 N/A N/A N/A 
H28 680000 70 0 N/A N/A N/A 
H29 1580000 0 40 Candida albicans  N/A N/A 
H30 1060000 0 0 N/A N/A N/A 
H31 570000 0 0 N/A N/A N/A 
H32 2000000 90 50 
Candida 
dubliniesis  N/A N/A 
H33 1440000 0 0 N/A N/A N/A 
H34 490000 0 0 N/A N/A N/A 
H35 740000 20 0 N/A N/A N/A 
H36 1720000 30 0 N/A N/A N/A 
H37 360000 0 10 Candida albicans  N/A N/A 
H38 124000 0 0 N/A N/A N/A 
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H39 84000 0 0 N/A N/A N/A 
H40 2040000 0 0 N/A N/A N/A 
H41 560000 0 0 N/A 
Klebsiella 
pneumoniae N/A 
H42 900000 20 80  Candida albicans  N/A N/A 
H43 340000 0 0 N/A 
Enterobacter 
cloacae  N/A 
H44 140000 30 0 N/A 
Enterobacter 
cloacae  N/A 
H45 1480000 0 0 N/A N/A N/A 
H46 3320000 20   N/A N/A N/A 
H47 520000 40 0 N/A N/A N/A 
H48 132000 2480 0 N/A N/A N/A 
H49 4600000 4700 0 N/A N/A N/A 















   
Appendix F: Endotoxin Assay Results
 
Raw Data{Wavelength:415.0} Reading 1
1 2 3 4 5 6 7 8 9 10 11 12
A 0.601 0.555 0.58 0.572 0.586 0.554 0.535 0.57 0.628 0.637 0.568 0.566
B 0.583 0.549 0.561 0.552 0.573 0.528 0.543 0.523 0.595 0.608 0.552 0.557
C 0.56 0.54 0.555 0.557 0.585 0.544 0.543 0.55 0.532 0.498 0.586 0.541
D 0.526 0.506 0.524 0.551 0.546 0.51 0.533 0.537 0.593 0.619 0.591 0.46
E 0.435 0.43 0.558 0.539 0.566 0.513 0.542 0.54 0.583 0.594 0.598 0.546
F 0.298 0.307 0.566 0.54 0.56 0.546 0.505 0.531 0.588 0.592 0.589 0.565
G 0.232 0.193 0.532 0.538 0.55 0.518 0.513 0.533 0.607 0.595 0.572 0.598
H 0.038 0.04 0.484 0.511 0.521 0.518 0.511 0.515 0.589 0.597 0.564 0.57
Reading 2
1 2 3 4 5 6 7 8 9 10 11 12
A 0.605 0.557 0.582 0.576 0.591 0.556 0.538 0.571 0.635 0.644 0.583 0.589
B 0.587 0.552 0.562 0.555 0.576 0.531 0.544 0.524 0.601 0.615 0.578 0.582
C 0.564 0.544 0.557 0.56 0.585 0.544 0.544 0.551 0.594 0.597 0.613 0.559
D 0.548 0.528 0.533 0.552 0.551 0.524 0.535 0.541 0.597 0.624 0.596 0.46
E 0.52 0.511 0.558 0.54 0.565 0.511 0.543 0.54 0.586 0.597 0.603 0.548
F 0.455 0.451 0.564 0.541 0.561 0.546 0.506 0.531 0.592 0.595 0.592 0.568
G 0.382 0.317 0.531 0.538 0.551 0.519 0.513 0.532 0.61 0.598 0.576 0.6









Sample Repeat OD EU EU/sampleng/ml Mean Sample Repeat OD EU EU/sampleng/ml
C71 1 0.582 5.690544 45.52 4.55 4.48 C2 1 0.543 4.573066 36.58 3.66 3.63
2 0.576 5.518625 44.15 4.41 2 0.54 4.487106 35.90 3.59
C75 1 0.562 5.117479 40.94 4.09 4.01 C3 1 0.506 3.512894 28.10 2.81 3.1
2 0.555 4.916905 39.34 3.93 2 0.531 4.229226 33.83 3.38
C7 1 0.557 4.974212 39.79 3.98 4.01 C4 1 0.513 3.713467 29.71 2.97 3.19
2 0.56 5.060172 40.48 4.05 2 0.532 4.25788 34.06 3.41
C8 1 0.533 4.286533 34.29 3.43 3.65 C5 1 0.522 3.971347 31.77 3.18 3.08
2 0.552 4.830946 38.65 3.86 2 0.513 3.713467 29.71 2.97
C11 1 0.558 5.002865 40.02 4.00 3.8 C6 1 0.635 7.209169 57.67 5.77 5.87
2 0.54 4.487106 35.90 3.59 2 0.644 7.467049 59.74 5.97
C15 1 0.564 5.174785 41.40 4.14 3.88 C9 1 0.601 6.234957 49.88 4.99 5.15
2 0.541 4.515759 36.13 3.61 2 0.615 6.636103 53.09 5.31
C24 1 0.531 4.229226 33.83 3.38 3.46 C12 1 0.594 6.034384 48.28 4.83 4.87
2 0.538 4.429799 35.44 3.54 2 0.597 6.120344 48.96 4.90
C26 1 0.493 3.140401 25.12 2.51 2.71 C13 1 0.597 6.120344 48.96 4.90 5.21
2 0.51 3.627507 29.02 2.90 2 0.624 6.893983 55.15 5.52
C28 1 0.591 5.948424 47.59 4.76 4.36 C14 1 0.586 5.805158 46.44 4.64 4.77
2 0.556 4.945559 39.56 3.96 2 0.597 6.120344 48.96 4.90
C33 1 0.576 5.518625 44.15 4.41 3.9 C17 1 0.592 5.977077 47.82 4.78 4.82
2 0.531 4.229226 33.83 3.38 2 0.595 6.063037 48.50 4.85
C10 1 0.585 5.776504 46.21 4.62 4.15 H2 1 0.61 6.492837 51.94 5.19 5.06
2 0.544 4.601719 36.81 3.68 2 0.598 6.148997 49.19 4.92
C16 1 0.551 4.802292 38.42 3.84 3.53 H3 1 0.593 6.005731 48.05 4.80 4.9
2 0.524 4.028653 32.23 3.22 2 0.601 6.234957 49.88 4.99
C18 1 0.565 5.203438 41.63 4.16 3.54 H4 1 0.583 5.719198 45.75 4.58 4.65
2 0.511 3.65616 29.25 2.92 2 0.589 5.891117 47.13 4.71
C31 1 0.561 5.088825 40.71 4.07 3.9 H6 1 0.578 5.575931 44.61 4.46 4.51
2 0.546 4.659026 37.27 3.73 2 0.582 5.690544 45.52 4.55
C34 1 0.551 4.802292 38.42 3.84 3.48 H7 1 0.613 6.578797 52.63 5.26 4.65
2 0.519 3.885387 31.08 3.11 2 0.559 5.031519 40.25 4.03
C38 1 0.521 3.942693 31.54 3.15 3.11 H9 1 0.596 6.091691 48.73 4.87 3.32
2 0.517 3.82808 30.62 3.06 2 0.46 2.194842 17.56 1.76
C48 1 0.538 4.429799 35.44 3.54 3.92 H11 1 0.603 6.292264 50.34 5.03 4.4
2 0.571 5.375358 43.00 4.30 2 0.548 4.716332 37.73 3.77
C50 1 0.544 4.601719 36.81 3.68 3.45 H12 1 0.592 5.977077 47.82 4.78 4.51
2 0.524 4.028653 32.23 3.22 2 0.568 5.289398 42.32 4.23
C51 1 0.544 4.601719 36.81 3.68 3.76 H13 1 0.576 5.518625 44.15 4.41 4.69
2 0.551 4.802292 38.42 3.84 2 0.6 6.206304 49.65 4.97
C54 1 0.535 4.34384 34.75 3.48 3.55 H14 1 0.567 5.260745 42.09 4.21 4.28
2 0.541 4.515759 36.13 3.61 2 0.573 5.432665 43.46 4.35










0.04 0.1 0.26 0.64 1.6 4 10
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Raw Data{Wavelength:415.0} Second reading
1 2 3 4 5 6 7 8 9 10 11 12
A 0.658 0.386 0.316 0.323 0.31 0.936 0.571 0.389 0.329 0.328 0.335 0.58
B 0.593 0.334 0.352 0.305 0.295 0.567 0.621 0.395 0.264 0.28 0.34 0.587
C 0.542 0.342 0.314 0.385 0.318 0.324 0.606 0.387 0.297 0.317 0.344 0.583
D 0.577 0.37 0.336 0.394 0.348 0.243 1.062 0.404 0.313 0.304 0.321 0.569
E 0.486 0.406 0.366 0.502 0.329 0.267 0.881 0.478 0.317 0.315 0.293 0.574
F 0.303 0.321 0.421 0.405 0.479 0.388 0.701 0.532 0.308 0.3 0.316 0.313
G 0.099 0.079 0.574 0.379 0.446 0.898 0.844 0.626 0.314 0.305 0.301 0.361










Sample Repeat OD EU EU/sampleng/ml Mean Sample Repeat OD EU EU/sampleng/ml
C1 1 0.316 2.216925 17.7354 1.77354 1.81 C61 1 0.881 8.951132 71.60906 7.160906 5.24
2 0.323 2.300358 18.40286 1.840286 2 0.478 4.147795 33.18236 3.318236
C19 1 0.352 2.646007 21.16806 2.116806 1.89 C62 1 0.701 6.805721 54.44577 5.444577 4.64
2 0.305 2.085816 16.68653 1.668653 2 0.532 4.791418 38.33135 3.833135
C20 1 0.314 2.193087 17.5447 1.75447 2.09 C63 1 0.844 8.510131 68.08105 6.808105 5.77
2 0.385 3.039333 24.31466 2.431466 2 0.626 5.9118 47.2944 4.72944
C21 1 0.336 2.455304 19.64243 1.964243 2.24 C65 1 1.131 11.93087 95.44696 9.544696 8.16
2 0.394 3.146603 25.17282 2.517282 2 0.84 8.462455 67.69964 6.769964
C22 1 0.366 2.812872 22.50298 2.250298 2.9 C69 1 0.329 2.371871 18.97497 1.897497 1.89
2 0.502 4.43385 35.4708 3.54708 2 0.328 2.359952 18.87962 1.887962
C23 1 0.421 3.468415 27.74732 2.774732 2.7 C70 1 0.264 1.597139 12.77712 1.277712 1.35
2 0.405 3.277712 26.22169 2.622169 2 0.28 1.787843 14.30274 1.430274
C25 1 0.574 5.292014 42.33611 4.233611 3.3 C71 1 0.297 1.990465 15.92372 1.592372 1.69
2 0.379 2.967819 23.74255 2.374255 2 0.317 2.228844 17.83075 1.783075
C27 1 0.54 4.88677 39.09416 3.909416 2.8 C78 1 0.313 2.181168 17.44934 1.744934 1.7
2 0.309 2.133492 17.06794 1.706794 2 0.304 2.073897 16.59118 1.659118
C29 1 0.31 2.145411 17.16329 1.716329 4.7 C80 1 0.317 2.228844 17.83075 1.783075 1.77
2 0.936 9.606675 76.8534 7.68534 2 0.315 2.205006 17.64005 1.764005
C30 1 0.295 1.966627 15.73302 1.573302 2.87 C86 1 0.308 2.121573 16.97259 1.697259 1.66
2 0.567 5.208582 41.66865 4.166865 2 0.3 2.026222 16.20977 1.620977
C34 1 0.318 2.240763 17.9261 1.79261 1.82 C87 1 0.314 2.193087 17.5447 1.75447 1.71
2 0.324 2.312277 18.49821 1.849821 2 0.305 2.085816 16.68653 1.668653
C36 1 0.348 2.598331 20.78665 2.078665 1.58 C89 1 0.364 2.789035 22.31228 2.231228 2.1
2 0.243 1.346841 10.77473 1.077473 2 0.336 2.455304 19.64243 1.964243
C41 1 0.329 2.371871 18.97497 1.897497 1.6 C90 1 0.335 2.443385 19.54708 1.954708 3.12
2 0.267 1.632896 13.06317 1.306317 2 0.58 5.363528 42.90822 4.290822
C42 1 0.479 4.159714 33.27771 3.327771 2.89 C98 1 0.34 2.50298 20.02384 2.002384 3.18
2 0.388 3.075089 24.60072 2.460072 2 0.587 5.446961 43.57569 4.357569
C45 1 0.446 3.766389 30.13111 3.013111 5.17 H16 1 0.344 2.550656 20.40524 2.040524 3.18
2 0.898 9.153754 73.23004 7.323004 2 0.583 5.399285 43.19428 4.319428
C46 1 1.044 10.89392 87.15137 8.715137 8.2 H18 1 0.321 2.27652 18.21216 1.821216 3
2 0.937 9.618594 76.94875 7.694875 2 0.569 5.23242 41.85936 4.185936
C47 1 0.571 5.256257 42.05006 4.205006 3.34 H19 1 0.293 1.942789 15.54231 1.554231 2.89
2 0.389 3.087008 24.69607 2.469607 2 0.574 5.292014 42.33611 4.233611
C53 1 0.621 5.852205 46.81764 4.681764 3.6 H20 1 0.316 2.216925 17.7354 1.77354 1.76
2 0.395 3.158522 25.26818 2.526818 2 0.313 2.181168 17.44934 1.744934
C56 1 0.606 5.673421 45.38737 4.538737 3.49 H22 1 0.301 2.038141 16.30513 1.630513 1.92
2 0.387 3.06317 24.50536 2.450536 2 0.361 2.753278 22.02622 2.202622
C60 1 1.062 11.10846 88.8677 8.88677 5.75 H23 1 0.33 2.38379 19.07032 1.907032 2
2 0.404 3.265793 26.12634 2.612634 2 0.349 2.61025 20.882 2.0882
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Appendix G: Statistical analysis 
 
 
Question 1: Do cancer patients carry a higher count of S. aureus compared to healthy individuals (cfu/ml)? 
Question 2: Do cancer patients carry a higher count of Streptococci compared to healthy individuals (cfu/ml)? 
Question 3: Do cancer patients carry a higher count of Candida compared to healthy individuals (cfu/ml)? 
Question 4: Do cancer patients carry higher count of endotoxin compared to healthy individuals (ng/ml)? 
 
Summary of results 
Count Cancer: Median (IQR) Healthy: Median (IQR) p-value (Mann- Whitney 
test) 
S. mutans (cfu/ml) 1110000 (1879000) 720000 (1327000) 0.020 
S. aureus (cfu/ml) 50 (246) 30 (70) 0.310 
Candida (cfu/ml) 55 (265) 45 (70) 0.567 




   
 
Descriptive statistics of cancer patients: organism and endotoxin count 
Patients=1
Descriptive Statistics (Stats table)
Variable







S. aureus count cfu/ml
S. mutans counts cfu/ml
Candida counts cfu/ml
Endotoxin count ng/ml
52 1939 50 10.00 15000 14.0 260 14990 246 4706
100 2142950 1110000 87000.00 24880000 501000.0 2380000 24793000 1879000 3274759
56 693 55 10.00 10000 20.0 285 9990 265 1733
61 4 4 1.35 8 2.9 4 7 1 1
 
Descriptive statistics of healthy individuals: organism and endotoxin count 
Patients=0
Descriptive Statistics (Stats table)
Variable







S. aureus count cfu/ml
S. mutans counts cfu/ml
Candida counts cfu/ml
Endotoxin count ng/ml
18 433 30.0 10.00000 4700 20.0 90 4690 70 1210
50 1121724 720000.0 0.00000 4600000 253000.0 1580000 4600000 1327000 1110677
10 1149 45.0 10.00000 6000 10.0 80 5990 70 2354






   
 
Mann-Whitney test for cancer patients and healthy individuals: organism and endotoxin count 
Mann-Whitney U Test (w/ continuity correction) (Stats table)
By variable Patients














S. aureus count cfu/ml
S. mutans counts cfu/ml
Candida counts cfu/ml
Endotoxin count ng/ml
1922.000 563.000 392.000 1.014543 0.310324 1.023737 0.305960 52 18 0.313273
8131.500 3193.500 1918.500 2.316292 0.020543 2.316350 0.020540 100 50
1908.500 302.500 247.500 0.572281 0.567132 0.574467 0.565652 56 10 0.566541
2326.000 677.000 435.000 -0.659140 0.509806 -0.659170 0.509787 61 16 0.513435
 
Question 5: Do cancer patients with gram negative bacteria (GNB) have a higher count of endotoxin compared to cancer patients without GNB 
(ng/ml)? 
Summary of results 
Count GNB: Yes- Median (IQR)  GNB: No- Median (IQR) p-value (Mann-Witney test) 
Cancer Patients: Endotoxin 
(ng/ml) 





   
Descriptive statistics of endotoxin count (ng/ml): cancer patients with GNB 
GNB/no GNB=1
Descriptive Statistics (Stats table)
Include condition: v2=1
Variable







Endotoxin count ng/ml 23 3.387826 3.490000 1.350000 5.770000 2.870000 3.920000 4.420000 1.050000 1.189434
 
 Descriptive statistics of endotoxin count (ng/ml): cancer patients without GNB 
GNB/no GNB=0
Descriptive Statistics (Stats table)
Include condition: v2=1
Variable







Endotoxin count ng/ml 38 3.761053 3.615000 1.580000 8.200000 2.800000 4.770000 6.620000 1.970000 1.559996
 
 
The Mann-Witney test for endotoxin count (ng/ml): cancer patients with and without GNB 
Mann-Whitney U Test (w/ continuity correction) (Stats table)
By variable GNB/no GNB















Endotoxin count ng/ml 662.5000 1228.500 386.5000 -0.744062 0.456840 -0.744091 0.456822 23 38 0.455335
 
100 
   
 
Question 6: Do cancer patients with oral mucositis have a higher count of endotoxin compared to healthy individuals (ng/ml)? 
Summary of results 
Count Cancer: Mucositis Median 
(IQR) 
Healthy: Median (IQR) p-value (Mann- Whitney test) 
Endotoxin (ng/ml) 4 (3) 4.3 (2) 0.889 
 
Descriptive statistics of endotoxin count (ng/ml): cancer patients with oral mucositis 
Patients=1
Descriptive Statistics (Stats table)
Exclude condition: v9=0 and v2=1
Variable







S. aureus count cfu/ml
S. mutans counts cfu/ml
Candida counts cfu/ml
Endotoxin count ng/ml
7 160 20 10.0 730 18.0 280 720 262 269
12 2405250 1225000 150000.0 9520000 685000.0 2510000 9370000 1825000 2943020
9 1021 210 10.0 3840 40.0 1040 3830 1000 1591







   
Descriptive statistics of endotoxin count (ng/ml): healthy individuals 
Patients=0
Descriptive Statistics (Stats table)
Exclude condition: v9=0 and v2=1
Variable







S. aureus count cfu/ml
S. mutans counts cfu/ml
Candida counts cfu/ml
Endotoxin count ng/ml
18 433 30.0 10.00000 4700 20.0 90 4690 70 1210
50 1121724 720000.0 0.00000 4600000 253000.0 1580000 4600000 1327000 1110677
10 1149 45.0 10.00000 6000 10.0 80 5990 70 2354
16 4 4.3 1.76000 5 2.9 5 3 2 1
 
Mann-Whitney test for endotoxin count (ng/ml): cancer patients with oral mucositis and healthy individuals 
Mann-Whitney U Test (w/ continuity correction) (Stats table)
By variable Patients
Marked tests are significant at p <.05000





















   
Question 7: Do cancer patients with oral mucositis have a higher count of endotoxin compared to cancer patients without oral mucositis 
(ng/ml)? 
 
Summary of results 
Count Cancer: Oral mucositis: 
Median (IQR) 
Cancer: No oral mucositis: 
Median (IQR) 
p-value (Mann- Whitney test) 
Endotoxin (ng/ml) 3.745 (2.515) 3.53 (1.14) 0.6501 
    
 
Question 8: Do cancer patients have a higher carrier rate of S. aureus compared to healthy individuals (%)? 
 
Summary of results 
Population S. aureus (%)- Present S. aureus (%)-  Not Present p- value (chi-squared test) 
Cancer Patients 52 48 P=0.064 





   
Frequency tables: S. aureus in cancer patients and healthy individuals 
Summary Frequency Table (Stats table)
Marked cells have counts > 10












0 32 18 50
64.00% 36.00%
1 48 52 100
48.00% 52.00%
All Grps 80 70 150
 
 
Question 9: Do cancer patients have a higher carrier rate of Candida compared to healthy individuals (%)? 
Summary of results 
Population Candida (%)- Present Candida (%)-  Not Present p- value (chi-squared test) 
Cancer Patients 56 44 P=0.000 






   
Frequency tables for Candida in cancer patients and healthy individuals 
Summary Frequency Table (Stats table)
Marked cells have counts > 10












0 40 10 50
80.00% 20.00%
1 44 56 100
44.00% 56.00%
All Grps 84 66 150
 
 
Question 10: Do cancer patients have a higher carrier rate of GNB compared to healthy individuals (%)? 
Summary of results 
Population GNB (%)- Present GNB (%)-  Not Present p- value (chi-squared test) 
Cancer Patients 24 76 P=0.154 
Healthy Individuals 14 86 
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